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ABSTRACT 
 
Adult acute myeloid leukemia (AML) effectively illustrates the challenges of 
contemporary cancer drug discovery and development, as molecularly 
targeted therapies have not yet been translated in clinical practice. In fact the 
standard therapy (cytarabine and an anthracycline) for AML has not been 
changed in over 40 years. As a consequence, outcome remains poor with 
overall survival of 30-40%. The genetic alterations that are associated with 
AML have been mapped out, but the underlying disease mechanism is poorly 
defined due to large inter-patient heterogeneity. In contrast, chronic myeloid 
leukemia (CML) is strictly driven by BCR-ABL1 and drugs targeting the ABL1 
kinase activity have paved the way for oncoprotein targeting drugs in the 
treatment of cancer. In CML the main clinical challenge is instead the 
emergence of resistance to ABL1-directed therapy. This resistance typically 
occurs through point mutations in the kinase domain of ABL1 such as the 
clinically challenging T315I mutation. Hence, in both leukemia types there is 
an unmet need for novel therapeutic strategies. 
 
This study focused on development and implementation of an Individualized 
Systems Medicine (ISM) platform to identify novel therapeutic strategies for 
leukemia patients. The ISM strategy incorporated functional ex vivo drug 
sensitivity and resistance testing (DSRT), deep molecular profiling and clinical 
information to facilitate identification of personalized therapy approaches. A 
large number of approved and investigational anti-cancer compounds were 
tested and individualized selective responses were quantified with drug 
sensitivity scores (DSS). RNA and exome sequencing data was used to 
identify genetic alterations that enabled associating drug sensitivities with 
genetic alterations and biomarkers. 
 
The DSRT approach enabled functional taxonomy of AML patient samples 
based on drug responses, provided insights into disease biology, and 
identified effective drugs and drug combinations for individual patients and 
thus facilitated drug repurposing. In addition, integration of DSRT and 
molecular data identified phenotype to genotype links that has a potential for 
rapid translation of results. Clinical implementation of ISM data was plausible 
in approximately 80% of relapsed and refractory AML patient cases, and 
meaningful and evaluable responses were achieved in approximately 40% of 
cases. Notably, emergence of in vivo resistance to targeted therapy was 
mirrored in the DSRT profile of the relapsed samples, highlighting a solid 
correlation between ex vivo and in vivo drug responses. Finally, this study 
identified a number of kinase inhibitors that can be repositioned for specific 
subtypes of AML and CML, such as dasatinib in combination with a FLT3 
inhibitor for AML patients with FLT3-ITD mutations and axitinib for patients 
with BCR-ABL1(T315I)-driven leukemia. 
 
The results of this thesis demonstrate how unbiased drug sensitivity profiling 
of patient-derived cancer cells is a powerful way to discern unforeseen drug-
disease and drug-target links with clinical implications and provides a 
workable concept that can be implemented in routine clinical care of cancer 
patients in the future.  
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INTRODUCTION 
 
The molecular characterization of various cancer types has dominated the 
cancer research field in recent years. However, this information has not led to 
significant advances in cancer therapy and clinical outcome of patients as 
judged by increase in cancer incidence, drug resistance, and underlying 
genetic complexity and heterogeneity1-4. Our functional understanding of the 
fundamental disease mechanisms is very limited and it is imperative to 
develop ways to systematically study cancer patient cells in order to 
effectively link functional profiles to cancer genotypes. Moreover, majority of 
cancers do not harbor druggable genetic aberrations that can be directly 
associated with existing drugs. For instance, mutations in the RAS genes 
occur in over 30% of cancers and yet its therapeutic targeting remains a 
significant challenge5. Thus, genotype to phenotype translation is not a simple 
task as even when drugs exist for a particular target, the cancer cells are 
predominantly not sensitive to direct inhibition of the oncoprotein due to cell 
plasticity, tumor heterogeneity, and compensatory signals6. Although 
comprehensive efforts to identify cancer-relevant genes are now routine, the 
assessment for their potential therapeutic targeting is largely an impromptu 
exercise not fully utilizing the vast array of data available7. 
 
Since there is a significant inter and intra-patient heterogeneity in cancer, 
individualized and combinatorial treatments will be necessary to attain 
meaningful responses. Customizable treatment strategies might be difficult to 
forecast only based on the genomic attributes of the cancer cells. Thus, it is 
evident that there is a need to extend the structural understanding of cancer 
genomes and supplement it with functional profiling of cancer cells6. There is 
an increasing number of molecularly targeted drugs available pre-clinically 
and clinically and this provides an unprecedented opportunity to 
comprehensively profile individual cancer patient samples in terms of 
molecular drivers, molecular mechanisms of disease as wells as personalized 
therapy options. Phenotypic drug sensitivity can aid in reading the cancer 
genome and provide a suitable alternative to the classical genotype to 
phenotype dogma where functional profiles can link to genetic alteration 
patterns. This strategy has potential for immediate translation of results 
especially when combined with clinical patient information.  
 
To gain a functional understanding of cancer patient cells, this study aimed to 
develop and implement a novel ex vivo high throughput drug sensitivity and 
resistance testing (DSRT) screening platform that covers the entire approved 
cancer pharmacopeia and emerging investigational anti-cancer drugs. More 
specifically the goal was to identify: underlying signaling pathways and 
processes driving cancer progression; individualized therapy options; 
mechanisms of drug sensitivity and resistance; and cancer drugs that can be 
repurposed for other cancer indications. This study focused on patients with 
hematological malignancies such as acute and chronic myeloid leukemia, for 
which there is a need of novel treatment strategies as well as a deeper 
understanding of drug resistance and disease progression mechanisms. 
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REVIEW OF THE LITERATURE 
 
1. Acute Myeloid Leukemia 
 
Acute myeloid leukemia (AML) is a hematological malignancy affecting blood 
cells committed to the myeloid linage of development. The disease is defined 
by the cancerous conversion of bone marrow-derived progenitor cells, which 
are characterized with a reduced rate of self-apoptosis and aberrant 
differentiation. In AML, rapid growth of abnormal, immature white blood cells 
(WBC; known as blasts) overpopulates the bone marrow and interferes with 
normal hematopoiesis8,9 (Figure 1). According to the World Health 
Organization (WHO) criteria10 at least 20% blasts of the myeloid lineage have 
to be detected in the bone marrow of a patient to warrant an AML diagnosis. 
AML is a heterogeneous clonal disease that is often accompanied with 
accumulation of somatically acquired gene mutations in hematopoietic 
progenitor cells, which lead to changes in cell renewal, proliferation and 
differentiation translating to differences in response to therapy and overall 
survival11,12. Disease progression in AML is very rapid and can be deadly 
within weeks or months if not treated. Patients most commonly succumb to 
the disease due to bone marrow failure13. 
 
Figure 1. Giemsa staining of acute myeloid leukemia blasts in bone marrow (left) 
and peripheral blood (right). Courtesy of Satu Mustjoki. 
 
AML is the most common type of acute leukemia in adults (accounting for 
25% of all leukemias) and its incidence increases with age with the mean age 
of diagnosis of 67-7014. According to most recent statistics, AML is diagnosed 
in approximately 21,000 individuals per year in the United States and results 
in approximately 10,500 deaths. Moreover, AML is more prevalent in males 
than in females with male-to-female ratio of 1.5:115. 
 
1.1 Etiology, signs and symptoms of AML 
 
Several risk factors have been described for AML onset. However, only a 
small fraction of AML cases can be attributed to known risk factors such as 
age, previous hematological disorders, genetic conditions, exposure to 
radiation, harmful substances (e.g. benzene) or chemotherapy. Majority of 
AML patients present with weight-loss, unexplainable fatigue and fever. Most 
of the symptoms can be explained by bone marrow deterioration such as 
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anemia, neutropenia, and thrombocytopenia. AML diagnosis can be obtained 
following blood cell count evaluation as well as profiling of the bone marrow 
aspirates/biopsies by microscopy, flow cytometry, immunohistochemistry, and 
cytogenetics14,16.  
 
1.2 Therapy and treatment outcome in AML 
 
The standard therapy for AML has not been changed in over 40 years and 
primarily consists of cytarabine and an anthracycline (e.g. idarubicin, 
daunorubicin or doxorubicin)9,17,18. The main goal of AML treatment is to 
achieve and preserve complete remission (CR), which is defined as bone 
marrow with less than 5% blasts. Treatment of AML is carried out in two 
phases, namely remission induction therapy and post-remission therapy. 
During induction therapy, a reduction of the number of malignant cells in the 
bone marrow is desired so that normal blood cell production can be resumed. 
Using standard therapy, approximately 65-85% of younger patients and less 
than 50% of older patients achieve remission19,20. However, long-term survival 
following remission induction therapy is only 30% with treatment related 
mortality of 5-10%. Post-induction therapy most commonly consists of 
standard dose cytarabine or hematopoietic stem cell transplantation (HSCT) 
for high-risk patients if a donor match is found. Two types of post-remission 
therapy have been characterized: consolidation therapy and maintenance 
therapy. Consolidation therapy is necessary to achieve prolonged remission, 
since patients that do not receive it most commonly relapse in 6-9 months21,22. 
Maintenance therapy, normally perceived as less myelosuppressive, in 
comparison to induction or consolidation therapy is given to patients that have 
already achieved CR. Its main aim is to prevent a relapse and to further 
reduce the number of the remaining leukemic cells.  
 
Even though there has been considerable progress in improving the care and 
treatment options of newly diagnosed AML patients, still 20-40% of patients 
never achieve CR with standard induction therapy and in addition 50-70% of 
patients that do achieve CR relapse within 3 years23. Prognosis of patients 
that relapse following a CR is poor. The length of the first remission is a 
relatively good predictor of the likelihood of a second CR and survival24. 
Moreover, possible treatment options for AML patients are heavily dependent 
on the age of the patient, as older patients have significantly lower survival 
and remission rates, experience more treatment related toxicity, have shorter 
disease free survival and shorter overall survival times12,25,26. 
 
Efforts have been made to identify alternative treatment strategies that can 
improve the remission rate and quality thereof, but have been largely 
unsuccessful to date.  Although a large percentage of AML patients under the 
age of 60 achieve CR following standard anthracycline and cytarabine-based 
therapy, long-term survival is fairly poor with only 40% of patients being alive 
at 5 years27,28. The long-term prognosis for high-risk AML patients (defined as 
either older than 65, having had previous myelodysplastic syndrome (MDS) or 
having secondary AML due to environmental exposures or previous treatment 
with chemotherapy) is even poorer with CR achieved in less than 40% of the 
cases and survival rates of less than 10%13,29,30. Approximately 10-14% of 
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patients will fail induction chemotherapy due to either treatment complications 
or refractory disease. A large proportion of patients achieve remission 
following the first induction therapy. The degree of blast cell reduction during 
initial course of chemotherapy has significant prognostic ramifications for 
disease relapse following remission. Hence, lower blast reduction confers 
higher relapse risk31,32. 
 
2. Classification of AML 
 
The French-American-British (FAB) Cooperative Group established the initial 
classification system for AML33. This system recognizes eight different AML 
subtypes (M0-M7), largely based on morphology and immunohistochemistry 
of lineage markers (Table 1)34. The FAB classification required 30% blasts to 
be present in the bone marrow for an AML diagnosis. However in 1999 a new 
system for disease stratification was introduced by the WHO, which reduced 
the blast minimum to 20%10,35.   
 
Table 1. Classification of AML based on French-American-British (FAB) criteria  
Subtype Morphological features Prevalence % 
AML-M0 Undifferentiated acute myeloblastic leukemia 5 
AML-M1 Acute myeloblastic leukemia with minimal maturation 15 
AML-M2 Acute myeloblastic leukemia with maturation 25 
AML-M3 Acute promyelocytic leukemia 10 
AML-M4 Acute myelomonocytic leukemia 20 
AML-M4 eos Acute myelomonocytic leukemia with eosinophilia 5 
AML-M5 Acute monocytic leukemia 10 
AML-M6 Acute erythroid leukemia 5 
AML-M7 Acute megakaryoblastic leukemia 5 
Modified from the review by Chandra Kumar, Genes Cancer, 201113 
 
The WHO system includes morphology as well as novel prognostic markers 
such as cytogenetics, molecular genetics, immunologic markers, and clinical 
features to divide patients into subgroups that have prognostic and 
therapeutic implications. Four broad AML subtypes are defined in the WHO 
classification: 1) AML with recurrent genetic abnormalities; 2) AML with 
multilineage dysplasia; 3) therapy related AML and MDS; and 4) those that do 
not fall in any of the above mentioned groups (largely encompassing the FAB 
subtypes; Table 2)13,35. This classification scheme created over 17 different 
subclasses of AML, facilitating clinicians to identify patient’s subgroups that 
can benefit from specific therapies. 
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Figure 2. The WHO stratification of AML. AML/ETO (RUNX1/MTG8); CBF-core 
binding factor; RARα-retinoic acid receptor alpha; MLL-	  Myeloid/lymphoid or mixed-
lineage leukemia; MDS-myelodysplastic syndrome.  
 
2.1 Cytogenetics in AML and its prognostic relevance 
 
As briefly touched upon previously, AML is a highly heterogeneous disease in 
terms of chromosomal abnormalities, gene mutations, and changes in gene 
expression. Close to 60% of all newly diagnosed patients have cytogenetic 
abnormalities such as nonrandom chromosomal translocations leading to 
gene rearrangements36. Currently the strongest independent predictor of AML 
patient outcome can be derived from cytogenetic and mutational analysis. 
Gene expression changes also represent important prognostic factors in 
terms of remission rate, relapse and overall survival13,36. Based on 
cytogenetics, AML patients can be divided in three large prognostic risk 
groups: favorable, intermediate and adverse27,37 (Table 2). 
 
2.2 Cytogenetic abnormalities with favorable prognosis 
 
Patients with favorable prognosis are ones with core-binding factor (CBF) 
leukemias, inv(16)/t(16;16) (CBFB-MYH11) or t(8;21) (RUNX1-RUNXIT1), 
accounting for 6-10% of cases, respectively18. These genetic aberrations lead 
to disruption of genes coding for distinct subunits of CBF38. Patients with 
these genetic changes typically do not require HSCT, as chemotherapy alone 
is sufficient for disease control. Roughly 30% of patients with CBF leukemias 
harbor activating mutations in KIT that confer adverse prognosis, lower 
remission durations and overall survival in comparison to CBF patients with 
wild-type KIT39,40. KIT mutations lead to constitutive activation of the receptor 
without the need of ligand. In addition to KIT mutations, Fms-like tyrosine 
kinase 3 (FLT3) activating internal tandem duplications (ITDs) have 
prognostically negative impact in CBF patients41. Another subgroup of 
favorable risk AML are patients with acute promyelocytic leukemia (APL) 
harboring the PML-RARα t(15;17) rearrangement, which disturbs the natural 
interaction of retinoic acid with RARα preventing RARα to be transformed to a 
transcription activator42. Patients have sustained long-term remissions and 
exceptional overall survival when treated with high-dose all-trans retinoic acid 
(ATRA; tretinoin), which specifically targets PML-RARα thereby overcoming 
the fusion-induced differentiation block. Patients that relapse or are refractory 
to ATRA can be salvaged with arsenic trioxide, which induces differentiation 
of the leukemic cells by degrading the abnormal fusion gene encoded 
protein43,44. Hence, it is vital to rapidly identify patients with APL and ensure 
that they receive appropriate treatment. 
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2.3 Normal karyotype AML 
 
The largest subgroup of AML patients (≈45%) exhibits a normal karyotype 
(NK) and falls into the intermediate risk group45. This disease group is very 
heterogeneous, mostly as a result of vast variability in gene mutations and 
gene expression46,47. Over a decade a ago, a ‘two hit model’ of leukemia 
pathogenesis was proposed48 with two broadly defined categories of gene 
mutations: class I that activate signaling pathways and in term stimulate 
hematopoietic progenitor cell proliferation and/or survival (e.g. mutations in 
KIT, FLT3, and RAS)39,49-51 and class II that influence transcription factors or 
components of the cell cycle machinery thereby affecting differentiation (e.g. 
CBF leukemia, APL, mutations in myeloid/lymphoid or mixed lineage leukemia 
(MLL) gene, brain and acute leukemia (BAAL) gene, Wilms tumor (WT1) 
gene, enhancer-binding protein α (CEBPα), nucleophosmin 1 (NPM1), and 
DNA methyltransferase (DNMT3A) gene)52-55. Often, cooperation between 
different mutations is seen in the pathogenesis of AML and this process is not 
random, as particular class I mutations preferentially cooperate with specific 
class II mutations56-58. Thus, enhanced molecular understanding of AML 
provides the basis for more comprehensive subclassification of the disease 
and sets postulates of prognosis estimation and therapy stratification. 
Currently, only mutations in NPM1, CEBRα and FLT3 are routinely tested in 
the clinic and have implications for patient care. 
 
2.4 AML with NPM1 mutations 
 
The most common mutation in NK patients is in the NPM1 gene, occurring in 
50% of cases. The overall prevalence of NPM1 mutations in adult AML is 
30%. The NPM1 gene encodes for a nucleolar phosphoprotein 
(nucleophosmin) that travels between the nucleus and cytoplasm and 
mutation in the gene influences the intracellular localization of NPM1. The 
mutation arises as a result of four base pair insertion at position 960 (exon 12 
of the gene) leading to an amplified export of the protein from the nucleus to 
the cytoplasm due to disruption of a C-terminal nuclear localization signal and 
creation of a new one16,59,60. Patients with mutated NPM1 present with high 
WBC count and growing number of circulating blasts with monocytic 
morphology. NPM1 mutations have been detected in leukemia-initiating cells 
and typically are stable over the disease course, indicating that these 
mutations occur early in AML development. However, the exact mechanism of 
NPM1-influenced leukemogenesis has not been elucidated to date. Overall, 
patients carrying the NPM1 mutation have favorable outcome with 
comparable prognosis as CBF AML61,62. In contrast, cooperation with FLT3-
ITD mutations (but not other cytogenetic abnormalities) confers poorer 
outlooks for patients62,63. Currently no targeted therapies against NPM1 
mutated AML have been developed and usually patients are treated with 
standard induction therapy and several cycles of high-dose cytarabine as 
consolidation therapy64. 
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2.5 AML with FLT3 mutations 	  
Twenty to thirty percent of AML patients harbor activating FLT3-ITDs in the 
juxtamembrane domain. Patients present with increased WBC count and 
typically have NK and therefore fall in the intermediate risk subgroup. In 
addition, activating tyrosine kinase domain mutations of FLT3 (FLT3-TKD) 
localized in the activation loop of the kinase have been detected. FLT3-TKD 
are less frequent (5-10%) than FLT3-ITD and their prognostic relevance is 
less clear, but appears to depend on cooperating mutations and genetic 
background65,66. FLT3 encodes for the receptor tyrosine kinase (RTK) FLT3 
belonging to the class 3 family of RTKs, which is targetable with small 
molecule kinase inhibitors67. Upon FLT3 ligand binding, FLT3 gets activated 
causing the instigation of downstream effector signaling pathways (e.g. 
STAT5, RAS, PI3K) thereby promoting the survival and proliferation of 
leukemic cells. Both alterations cause autophosphorylation of the FLT3 
receptor that in turn leads to increased cell proliferation, inhibition of apoptosis 
and activation of signaling pathways independent of a ligand68,69. The 
prognosis of NK-AML with FLT3-ITD is significantly worse than NK-AML 
patients without the mutation when treated with standard therapy70. Evidence 
exists that the outcome of FLT3-driven disease is linked with the ratio of 
mutant vs. wild-type allele where high allelic burden of the mutant envisages 
poorer survival37. Targeted therapies for FLT3 have been developed and are 
currently being investigated in clinical trials with quizartinib being the most 
potent and furthest in clinical development (currently in phase 3 trials for 
refractory AML patients with FLT3-ITD mutations; NCT02039726). In addition, 
HSCT could be a viable treatment option to consider in patients with FLT3-
ITD-positive AML45. 
 
2.6 AML with CEBPα 
 
CEBRα falls in the family of basic region leucine zipper transcription factors 
and influences granulocyte differentiation of common myeloid progenitors71. 
The frequency of CEBPα mutations in AML is approximately 5-15%, with 50% 
of mutations clustering in the N-terminus causing either a truncated 
nonfunctional protein or increased expression of the dominant-negative 
isoform of p30CEBPα. In contrast, mutations in the C-terminus result in an 
abnormal protein lacking DNA binding and/or homodimerization 
capabilities46,72. In 75% of cases, N- and C-terminus mutations are biallelic 
with most being compound heterozygous (N-terminal on one allele and C-
terminus on the other). CEBPα mutations are usually detected in NK-AML and 
in patients with 9q deletion9. Patients harboring CEBPα mutations generally 
have good clinical outcome analogous to AML patients with NPM1 mutations 
without FLT3-ITD70 (Figure 3). Interestingly, only biallelic CEBPα mutations 
are associated with favorable prognosis, whereas the survival of patients with 
monoallelic CEBPα mutations is comparable to AML patients with wild-type 
CEBPα72. This variable disease outlook is likely due to distinct gene 
expression (e.g. downregulation of HOX genes) and methylation pattern in 
double mutant cases, data for which comes from disease modeling in 
mice73,74. No targeted therapy is available for CEBPα mutant AML and the 
therapy recommendation is in line with that for NPM1-driven AML without 
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FLT3-ITD. There are not clear indications that patients with CEBPα mutations 
benefit from HSCT in first CR. 
 
 
Figure 3. Kaplan–Meier curves of relapse-free survival and overall survival of AML 
patients with: NPM1 mutations without FLT3-ITD (blue curve), biallelic CEBPα 
mutations (red), and with either FLT3-ITD or triple negative genotype (wild type 
NPM1 and CEPBα, and no FLT3-ITD; black). Adapted from Schlenk et al, N Engl J 
Med, 200862.  
 
2.7 Other molecular markers commonly identified in NK-AML 
 
The majority of patients (≈85%) with NK AML have a mutation or other genetic 
abnormality12, but their prognostic relevance is uncertain. In addition to 
NPM1, CEBPα and FLT3-ITD mutations, several other molecular markers are 
gaining prognostic and therapeutic importance such as DNMT3a, IDH1/2, 
TET2 and WT1.  
 
DNMT3a mutations 
DNMT3a mutations were identified by massive parallel sequencing of the 
genome of a NK AML patient55. DNMT3a is a DNA methytransferase that is 
responsible for adding methyl groups to cytosine residues of CpG 
nucleotides75. The frequency of DNMT3a mutations in de novo AML patients 
is 22-26%55,76. There has been an array of missense, nonsense, frame-shift, 
and splice-site mutations detected along the gene and they most frequently 
cluster at position R88255. The functional implication of DNMT3a mutations is 
still unclear but some reports exist that they result in either reduced DNA 
methylation activity (R882 mutations)77 or untimely truncation of the encoded 
protein (non-R882 mutations)75,78. There have been conflicting reports 
regarding the effect of DNMT3a mutations on DNA methylation and gene 
expression in AML. Ley and colleagues have found no tangible changes in 
methylation and gene expression55, whereas others have detected increased 
expression of HOX family genes77 or strong association between DNA 
methylation and DNMT3a mutation status79. Hence, it is largely unknown how 
this mutation impacts AML pathogenesis. However, recent large scale 
sequencing initiatives have determined that approximately 44% of AML 
patient samples harbor mutations in DNA methylation associated genes76, 
suggesting that abnormal DNA methylation is characteristic of AML and likely 
plays a role in the underlying mechanism of the disease80,81.  
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DNMT3a mutations confer poor outcome and do not occur in patients with 
favorable cytogenetics. Thus, mutations in DNTM3a primarily are detected in 
intermediate-risk patients (NK patients) with overall somatic mutation rate of 
12-3578. DNMT3a mutations commonly cooperate with NPM1, FLT3-ITD and 
IDH1 mutations, but are mutually exclusive with transcription factor fusions 
(e.g. PML-RARα), suggesting similar functions in initiation of AML 
pathogenesis76. Moreover, a study by Patel et al observed mutual exclusivity 
between DNMT3a mutations and MLL fusions82. In recent years, there has 
been increasing interest in determining the value of hypomethylating agents in 
patients with aberrant methylation. Decitabine and azacitidine are DNA-
methyltransferase inhibitors, which are clinically available for treatment of 
high-risk MDS. Decitabine exhibits its action by incorporating into DNA and 
blocking DNA synthesis, proliferation and stimulating apoptosis and myeloid 
differentiation83,84. Azacitidine, on the other hand, can incorporate into both 
DNA and RNA thus inhibiting DNA, RNA and protein synthesis and can also 
influence myeloid differentiation85. Their DNA incorporation ability occurs at 
sub-toxic doses by forming irreversible complexes with DNMT1 thereby 
sequestering and inhibiting the enzyme. In contrast, blocking of DNA and 
RNA synthesis is achieved at higher doses. Hence, these two drugs dot not 
inhibit DNMT3a directly86,87. These agents have been evaluated in clinical 
trials for AML patients with mixed results88-91. Decitabine and azacitidine have 
a favorable safety profile and potential clinical benefit, deserving further 
evaluation either as monotherapy or in combination with other drugs 
especially in older patient population unfit for standard induction 
chemotherapy.  
IDH1/2 mutations 
The importance of IDH1/2 mutations was first recognized in glioma and 
secondary glioblastoma, where the incidence is 70%92. More recently they 
have also been identified in AML with frequency of 6-16% and 8-19% for IDH1 
and IDH2, respectively76,93-95. Similarly as with DNMT3a, these mutations are 
increasingly found in patients with normal cytogenetics. Interestingly, IDH 
genes encode for metabolic enzymes playing a role in citrate metabolism, a 
crucial part of the Krebs cycle. Their normal function is to facilitate the 
oxidative decarboxylation of isocitrate giving rise to α-ketoglutarate (α-KG). 
IDH1/2 mutations are typically heterozygous, implying that they lead to 
enzymatic gain of function78 and indeed, the encoded oncoproteins attain a 
different enzymatic activity by which α-KG is reduced to 2-hydroxyglutarate 
(2HG), causing a rise of 2HG levels that inhibit α-KG-dependent reactions 
vital for normal DNA methylation96,97. IDH1/2 mutant protein expression 
negatively influences myeloid differentiation and leads to increased 
expression of stem cell markers, alluding to a role in block of differentiation of 
AML cells. Moreover, a signature of significant gain in methylation has been 
associated with IDH1/2 mutant AML76,98.  
 
IDH1/2 mutations often cooperate with NPM1 mutations, but are mutually 
exclusive with TET2 mutations. Conflicting reports, regarding the prognosis of 
AML patients with IDH1/2 mutation, have been published with some finding 
associations with worse prognosis, others with good or no association at 
all78,82. Patel et al found that co-occurring NPM1 and IDH mutations without 
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FLT3-ITD had a more favorable outcome than NPM1 mutant FLT3-ITD 
negative patients82. Hence, the bearing of IDH1/2 mutations on clinical 
outcome may be contingent on specific patient populations. Several IDH 
inhibitors have been developed and are currently in different stages of 
preclinical and clinical evaluation. Preclinical studies have shown that IDH 
inhibitors act by either reducing the hypermethylation states of histones and 
DNA, lowering the 2HG levels, preventing IDH1 to produce 2HG, or promoting 
differentiation99-101. Of note, AG-881, AG-120 and AG-221 are currently 
undergoing phase I studies in advanced hematologic malignancies with IDH1 
or IDH2 mutations (NCT02492737), IDH1 mutations only (NCT02074839), 
and IDH2 mutations only (NCT01915498), respectively. 
 
TET2 mutations 
TET2 mutations were first described in 2009 and are detected in 20% of MDS 
and secondary AML patients102 as well as 10-20% of AML patients. TET2 is a 
metabolic enzyme that catalyzes the conversion of 5-methylcytosine to 5-
hydroxymethylcytosine, which plays a role in DNA demethylation control103,104. 
Different types of TET2 mutations have been detected such as deletions, 
nonsense mutations and missense mutations, but their functional significance 
it unclear though they have been predicted to be inactivating102. In most 
patients heterozygous mutations have been detected, suggesting that TET2 
haploinsufficiency is sufficient to maintain the leukemia. TET2 mutant AML 
exhibits a gene hypermethylation phenotype alike IDH1/2 mutated AML98. 
TET2 mutations frequently co-occur with NPM1 and DNMT3a mutations, but 
are mutually exclusive with MLL-PTD and IDH1/2 mutations. A recent study 
has shown that TET2 mutations are not early leukemia initiating events, but 
rather occur later than NPM1 and DNMT3a105. 
 
WT1 mutations 
Five to thirteen percent of AML patients have mutations in the WT1 gene with 
enrichment in NK-AML76,82,106. WT1 encodes for a zinc-finger transcription 
factor involved in control of apoptosis, proliferation and differentiation of 
hematopoietic cells. The role of WT1 is paradoxical in that it was originally 
thought to be a tumor suppressor gene, but oncogenic roles have also been 
recognized107. The majority of large-scale studies indicate a poor prognosis 
association of WT1 mutations with reduced relapse-free survival and overall 
survival in comparison to WT1 wild-type patients, but this has not been 
corroborated in all studies likely due to differences in patient populations and 
presence of additional mutations108-110. Moreover, WT1 overexpression is 
detected in large proportion of AML patients. A recent study found that WT1 
mutations are predominant in females, younger patients, good outcome 
subgroups of patients with PML-RARα or biallelic CEBPα, and in patients with 
FLT3-ITD106. In contrast, mutual exclusivity was observed with ASXL1, IDH1/2 
and more recently with TET2 mutations111, and in patients with complex 
karyotypes82. Comparison of 35 paired diagnosis and relapse samples 
identified mutation instability and loss of the mutation at first relapse in 34% of 
cases. This finding suggests that WT1 mutations do not play a leukemia 
initiating role, but rather are secondary events106. WT1 mutations result in 
lowered levels of 5-hydroxymethylcytosine and reduced TET2 function in AML 
patients that leads to altered DNA methylation111. No specific therapies have 
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been implicated for patients with WT1 mutations or WT1 overexpression to 
date. 
 
2.8 High-risk AML 
AML patients falling into the high-risk stratification group most commonly have 
monosomies of chromosome 5 or 7, deletions of the long arm of chromosome 
3 and complex karyotype (at least three different genomic alterations)14. More 
recently, a distinct subgroup of patients has been identified with monosomal 
karyotype (MK; two or more monosomies or a single monosomy together with 
structural changes) that confers extremely poor prognosis and might serve as 
a better poor prognosis predictor than complex karyotype112,113. In fact, 
patients with noncomplex MK do as poorly as patients with complex MK with 
median survival of six months45,113. Hence, patients in this category could be 
considered for HSCT and/or investigational therapy. Genomic aberrations 
involving chromosomes 5 and 7 in the context of complex karyotype are 
frequently associated with TP53 deletions, which represent one of the most 
adverse markers in AML with very poor patient survival114,115. In addition, AML 
with myelodysplastic changes (often termed secondary AML) as well as 
therapy related (following cytotoxic therapy) AML has unfavorable prognosis, 
likely as a results of genomic aberrations overlapping with complex and 
monosomal karyotypes such as TP53 deletions and loss of chromosomes 5 
and 737. AML harboring MLL-fusions can also fall in the high-risk patients 
group, but the prognostic risk of MLL translocations is linked with the partner 
gene82. For patients with poor prognosis the only potentially curative 
treatment is HSCT. 
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Table 2. Overall risk assessment of AML in light of integrated genetic analysis 
 Overall risk Probability of overall survival 
Cytogenetic 
risk Good Intermediate Poor 
 
Favorable 
PML-RARα	   	   	  
60% 
CBF 
leukemia	   	   	  
biallelic 
CEBPα 
	   	  
Intermediate 
(normal 
karyotype) 
Mutant 
NPM1 and 
IDH1/2 
FLT3-ITD -	   	  
	  
80-90% 
	   wt ASXL1 
FLT3-ITD - 
	  
40% 
	   wt MLL-PTD 
FLT3-ITD -	   	  	   wt PHF6 
FLT3-ITD -	   	  	   wt TET2 
FLT3-ITD -	   	  	   Mutant CEBPα 
FLT3-ITD – or +	   	  	   wt MLL-PTD 
FLT3-ITD +	   	  	   wt TET2 
FLT3-ITD +	   	  	   wt DNMT3α 
FLT3-ITD +	   	  	   	   Mutant TET2 
FLT3-ITD -	  
10-15% 
	   	   Mutant MLL-PTD 
FLT3-ITD -	  	   	   Mutant ASXL1 
FLT3-ITD -	  	   	   Mutant PHF6 
FLT3-ITD -	  	   	   Mutant TET2 
FLT3-ITD + 	   	   Mutant MLL-PTD 
FLT3-ITD + 	   	   Mutant DNMT3α 
FLT3-ITD + 	   	   wt CEBPα 
FLT3-ITD + 
Unfavorable 
	   	   TP53 
0-5% 
	   	   Monosomy 7 	   	   Monosomy 5 	   	   5q deletion 	   	   Inv(3) or t(3;3) 	   	   Monosomal 
karyotype 	   	   Complex 
karyotype 
PTD: partial tandem duplication; wt: wild type. Adapted from Patel et al, N Eng J 
Med, 201282. 	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3. Genomic landscapes and clonal evolution of AML 
 
The genetic architecture of AML is relatively simpler than that of solid tumors 
with lesser genomic instability and an average rate of 13 mutations per 
patient76. Previous research has shown that individual hematopoietic stem 
cells harbor comparable number of mutations to the one detected in de novo 
AML patients, indicating that AML development occurs randomly in a cell that 
accidentally accumulates transforming combination of mutations116. The 
number of driver mutations that are required for a malignant transformation is 
not well defined, but the working hypothesis is that there are 5-7 driver 
mutations in epithelial cancers whereas that number may be lower in 
hematologic malignancies117. The recurrent mutations in AML are reasonably 
well outlined and grouped into functional classes (Figure 4).  
 
 
 
 
 
 
Figure 4. Percentage of significantly mutated genes and recurrent genomic 
aberrations in AML out of 200 patient samples evaluated in the AML TCGA study76. 
 
Based on the two-hit model of leukemia pathogenesis, briefly described 
above, AML initiating events are thought to be class II mutations (ones 
affecting transcription and cell differentiation; e.g. PML-RARα or MLL-fusions) 
with class I mutations (ones conferring proliferative advantage) occurring later 
in disease progression48,117. Co-occurrence and exclusivity analysis shows 
that certain mutations are synergistic whereas others are redundant, giving 
insights into the biology of AML. Studies in mice suggest that only two 
mutations are sufficient for AML initiation118,119 and this is corroborated in 
human genome sequencing studies with numerous AML patients harboring 
one or two identifiable driver mutations. While two driver mutations may be 
sufficient for leukemic transformation, the majority of patients carry three or 
more drivers at clinical presentation116.  
 
Two distinct concepts of cancer evolution have been proposed: linear and 
branching evolution (Figure 5). Sequential dominant clones arising as a result 
of step-wise acquisition of driver mutations define linear evolution. However, 
deep sequencing studies have shown that AML genomes are highly 
mutationally complex and variability and dominance of clones alter during the 
disease course120,121. Hence, due to the significant increase of genetic and 
clonal heterogeneity and the continuous accumulation of mutations it is likely 
that majority of tumors undergo branching evolution117. In AML majority of 
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disease-related mutations are common to all clones as the initiating event 
occurs in a cells with mutational history, whereas subclonal mutations account 
for 14% of total mutations116. Evidence exists that both linear and branching 
clonal evolution occurs in AML. In some cases only one mutation cluster is 
detected in the primary tumor that gains additional mutations at relapse in line 
with linear clonal architecture. In contrast, in other cases several mutation 
clusters are present in the primary and only certain subclones that evade 
therapy extinction survive and expand at relapse (branching clonal 
architecture)121. Moreover, several studies have shown that disease relapse in 
AML occurs as a result of re-emergence or evolution of the founding clone121-
123, indicating that the genetic heterogeneity of leukemic stem cells at 
diagnosis is the central problem. Questions arise whether combination of 
targeted therapies as first line treatment of AML will deliver improved 
outcomes, but success will likely depend on ability to target all clones and 
prevention of further clonal evolution that commonly occurs in response to 
therapy121. 
 
Figure 5. Graphical representation of linear and branching clonal evolution. Adapted 
from Grove and Vassiliou, Disease Models & Mechanisms, 2014117. 
 
4. Further therapeutic perspectives in AML 
 
While most AML patients can be comprehensively characterized based on 
cytogenetics and molecular markers, this has still not led to significant 
therapeutic advances. The cornerstone of AML treatment still remains 
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unspecific cytotoxic therapy with the exception of APL. Given the dismal 
outcome of refractory and older patients, novel therapies are urgently needed. 
Evidence exists that RTKs have a significant role in leukemogenesis and can 
serve as important targets for molecularly targeted therapy (Figure 6)124. One 
example of this is the development of FLT3 specific inhibitors, which are 
explored in clinical trials as monotherapy or in combination with conventional 
chemotherapy. Promising first in human study results have been observed for 
the second-generation inhibitor quizartinib in relapsed and refractory patients 
with FLT3-ITDs where 10 out 18 (56%) patients had a clinical response with 
median response duration and overall survival of 13.3 and 14 weeks, 
respectively125. Moreover, phase II trials gave additional proof of quizartinib’s 
efficacy as a single agent in FLT3-ITD positive AML126. Quizartinib acts by 
potent and selective inhibition of FLT3 resulting in rapid clearance of 
peripheral blasts and initiation of apoptosis in majority of FLT3-ITD driven 
AML. On the contrary, the effects in the bone marrow are typically not 
cytotoxic, but rather terminal differentiation initiating that is supported by flow 
cytometric analysis revealing increased expression of monocytic markers 
(CD15) and reduced expression of CD34 and CD117127. Several other FLT3 
inhibitors are at various stages of clinical development for treatment of AML 
such as sorafenib128,129 (currently in phase II in combinatorial setting), 
midostaurin130 (currently in phase III as single agent or combinatorial therapy), 
and crenolanib131,132 (currently in phase II; NCT01657682). Clinical challenges 
pertaining to FLT3 inhibitors are maintenance of an effective plasma 
concentration, lack of efficacy against both FLT3-ITDs and FLT3-TKD, QTc 
prolongation, and selection for resistant mutations133. It remains to be seen 
whether FLT3 specific inhibitors will reach the market and have an impact on 
the outcome of AML patients, especially for those with FLT3 mutations. 
 
As mentioned previously, KIT mutations are present in significant proportion 
of CBF AML patients. Hence, targeting the resulting RTK CD117 expressed 
on hematopoietic progenitor cells is an attractive strategy for this patient 
population. KIT signaling is involved in the regulation of proliferation, 
differentiation and apoptosis. Candidate agents are inhibitors of Abelson 
murine leukemia viral oncogene homolog 1 (ABL1), imatinib and dasatinib, 
which also target KIT with dasatinib currently explored in trials in combination 
with chemotherapy (NCT01876953)134. Moreover, aberrant activation of the 
MAPK pathway has been implicated in leukemogenesis135. The pathway is 
frequently deregulated in many cancer types including AML, as it plays a 
crucial role in regulation of cell proliferation. Mutations in NRAS and KRAS 
occur in 12-15% of all AML cases, but are most common in NK AML76. 
Several different agents exist with capabilities to in theory block the 
RAS/RAF/MEK/ERK cascade, however single agent approaches towards 
RAS-driven cancers including AML have not been successful and therefore 
tailored and more personalized combinatorial strategies would be needed to 
target those, likely involving specific RAF, MEK or ERK inhibitors as 
backbones. The MEK inhibitor selumetinib has been explored in phase I and II 
trials with modest single-agent efficacy and good safety profile136,137, 
indicating that it can be explored further for combinatorial approaches. 
Previous research has shown that the PI3K/AKT/mTOR138 and the 
JAK/STAT3/5139 pathways are frequently activated in AML135. Nonetheless, 
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there is little evidence that inhibiting these pathways with single agents would 
be an efficient strategy. While there is an indication that molecularly targeted 
therapy could have a distinct clinical implication for AML patients, the 
challenge remains in broadening the understanding of AML pathogenesis and 
identifying effective combinatorial regimens and subgroups of patients likely to 
benefit.  
 
Figure 6. Schematic representation of the FLT3 signaling pathway and potential 
points of inhibition with approved and emerging small molecule inhibitors. Adapted 
from Swords et al, Leukemia, 2012140. 
 
5. CML 
 
CML is a clonal hematopoietic stem cell malignancy affecting approximately 
one in 100,000 individuals and accounting for 15% of all new leukemia cases 
in Western countries. In line with AML, the disease is slightly more common in 
males than in females15,141 and the median age of diagnosis is 64142. BCR-
ABL1 is a unique diagnosis and disease monitoring biomarker for CML, which 
is amenable to drug targeting by ABL1 specific tyrosine kinase inhibitors. 
Diagnosis confirmation is achieved by detection of the Philadelphia 
chromosome and BCR-ABL1 transcripts in peripheral blood or bone marrow 
with chromosome banding analysis, FISH cytogenetics and/or quantitative 
PCR142.  
 
Three different disease stages have been recognized in CML according to 
clinical features and laboratory findings, with majority of patients presenting in 
the chronic phase. Without adequate medical intervention, the disease 
progresses to an accelerated phase and eventually to an acute-leukemia like 
disease known as blast crisis within 3-5 years141. In chronic phase the myeloid 
lineage is expanded but cell differentiation is preserved and patients are 
generally asymptomatic or present with mild fatigue, anemia, splenomegaly, 
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and/or weight loss143. Patients are increasingly being diagnosed by 
serendipitous finding of elevated WBC count in routine heath screening144. 
Accelerated phase and blast crisis (Figure 7) are largely distinguished on the 
proportion of blasts present in the blood and bone marrow of a patient with 
slightly different definitions according to the WHO (10-19% blasts in peripheral 
blood or bone marrow for AP; ≥20% BC)10 and European Leukemia Net (ELN; 
15-29% blasts for AP; ≥30% for BC)145 guidelines. The accelerated phase is 
important as it indicates that the disease is advancing and conversion to blast 
crisis is forthcoming. Moreover, the efficacy of drug treatment is reduced in 
patients with advanced disease. Besides the increasing blast count, blast 
crisis CML is defined by extramedullary proliferation of blasts, large blast foci 
in the bone marrow or spleen, and complete blockade of terminal 
differentiation141. Moreover, the progression to blast crisis CML is associated 
with the gain of additional mutations146. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. CML cells in lymphatic blast crisis in bone marrow. Courtesy of Satu 
Mustjoki. 
 
5.1 BCR-ABL1 
 
The first chromosomal aberration identified in cancer was the Philadelphia 
chromosome147. The Philadelphia chromosome is a shortened chromosome 
22 arising as a result of a reciprocal translocation of the ABL1 gene on 
chromosome 9 and breakpoint cluster (BCR) gene on chromosome 22 (Figure 
8). This translocation is detected in over 95% of CML patients, 25-30% of 
acute lymphoblastic leukemia (ALL) patients and very rarely in AML. The 
ABL1 gene is juxtaposed to the proximal part of the BCR gene, giving rise to 
an abnormal fusion gene BCR-ABL1 that encodes for a tyrosine kinase with 
constitutive activity essential for the oncogenic aptitude of BCR-ABL1148. 
BCR-ABL1 signals via numerous pathways such as the MAPK, PI3K/AKT, 
and JAK/STAT to enhance cellular proliferation, modify cell differentiation and 
prevent apoptosis (Figure 9)149. The breakpoints of the fusion vary ensuing 
various DNA amounts of BCR to be fused with ABL1 (exons 2-11). In CML the 
most common break position is between exons 12 and 16 known as the major 
breakpoint cluster region (M-bcr). However, in minor proportion of patients the 
disruption occurs more distally (between exons 19 and 20). On the other 
hand, in Philadelphia chromosome-positive (Ph+) ALL half of the patients 
have breaks within M-bcr and the other half have breaks distal to the first 
exon of BCR. Therefore, BCR-ABL1 proteins can range from 185 to 230 kDa 
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with the smallest containing less of BCR than the others, but all comprise of 
equal amount of ABL1148,150. The p210 BCR-ABL1 is found in almost all Ph+ 
CML patients and 30-35% of Ph+ ALL patients. 
 
 
Figure 8. Schematic representation of the formation of the Philadelphia 
chromosome. 
 
Human ABL1 has a molecular weight of 145-kDa and is ubiquitously 
expressed. However, in hematopoietic cells its levels decrease with myeloid 
maturation151. ABL1 is a non-receptor tyrosine kinase with variable biological 
functions. With its SH1 domain it phosphorylates substrate proteins thereby 
influencing key cellular activities such as increased proliferation, loss of 
stromal adhesion and resistance of apoptosis141. Moreover, ABL1 shuttles 
between the nucleus (has DNA binding ability) and the cytoplasm (binds to 
actin cytoskeleton)152, but in hematopoietic cells ABL1 is more commonly 
cytoplasmic151. While cytoplasmic ABL1 is involved in signaling and 
cytoskeletal molding, its functions in the nucleus have been connected to 
regulation of the cell cycle152 and genotoxicity153. The phosphorylation of 
ABL1 is strictly regulated most likely by motifs in the N-terminus, which are 
lost in the formation of BCR-ABL1 resulting in the constitutive kinase activity. 
Similarly, BCR travels between the nucleus and cytoplasm and its expression 
is reduced with myeloid maturation in hematopoietic cells154. The BCR gene 
contains many diverse functional motifs and in eukaryotes it plays a role in 
two main signaling processes155,156, phosphorylation and guanosine 
triphosphate (GTP) binding132,133. The first exon of BCR is crucial for 
oncogenic transformation as it is the only exon that is present in all known 
BCR-ABL1 fusion proteins. Moreover, the first exon has serine and threonine 
kinase actiivity with ability to phosphorylate itself and main substrates thereby 
transmitting cellular signals. There are also a number of Src-homology-2 
(SH2) binding domains in the first exon, which are critical for association of 
singnal transduction complexes148. 
 
Chromosome 9
ABL1
gene Chromosome 22
BCR
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Philadelphia
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Figure 9. A simplified cartoon of the BCR-ABL1 signaling network. BCR-ABL1 
dimerization initiates autophosphorylation and activation of the kinase and creates 
docking sites for adapter proteins (blue), which play a role in activation of 
downstream effector signals (green) that cummulatively lead to increased survival, 
block of appoptosis and changes in cell adhesion and migration. Adapted from 
O’Hare et al, Clin Cancer Res, 2011157. 
 
Table 3. Biological features of BCR-ABL1 protein variants 
 p190 BCR-
ABL1 
p210 BCR-
ABL1 
Constitutive tyrosine kinase activity ✓ ✓ 
Programed cell death attenuation ✓ ✓ 
Associated with JAK/STAT5 signaling  ✓ ✓ 
Associated with PI3K/AKT signaling ✓ ✓ 
Transforming activity partially mediated by RAS 
signaling ✓ ✓ 
May induce alterations in adhesion properties ✓ ✓ 
Induces ubiquitin-mediated degradation of Abelson 
interacting protein ✓  
Cytoskeletal actin binding  ✓ 
Activates Jun kinase  ✓ 
Interacts with and regulates DNA repair proteins  ✓ 
Interacts with KIT and IL-3 receptors  ✓ 
Upregulates production of IL-3  ✓ 
Modified from a review by Kurzrock et al, Ann Intern Med, 2003148.  
 
The level of oncogenic potential of BCR-ABL1 correlates with the level of 
tyrosine kinase activity158. Hence, the p190 BCR-ABL1 is linked with the 
development of more aggressive acute leukemia phenotype as it has the 
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highest tyrosine kinase activity, whereas the p210 BCR-ABL1 is responsible 
for the initiation of more indolent chronic leukemia phenotype148. The diverse 
biological features of the two protein variants of BCR-ABL1 are summarized in 
Table 3. 
 
5.2 Therapy and outcome of CML patients 
 
Prior to 1998, therapy for CML was limited to interferon α, busulfan, 
hydroxyurea, and HSCT with median patient survival of 5-7 years. Even 
though, these therapies have shown efficacy in patients with CML, their use is 
linked with adverse effects that have unfavorable impact on quality of life. 
Interferon α treatment could lead to complete hematologic remission, whereas 
only in a fraction of patients complete cytogenetic remission. In 1996, Brian 
Druker and colleagues discovered a specific ABL1 tyrosine kinase inhibitor 
(STI571; imatinib) and reported efficacy in CML cell lines in vitro159. First-in-
human studies in accelerated phase patients showed that imatinib controlled 
blood counts, restored chronic phase and induced cytogenetic responses in 
significant proportion of patients160. Moreover, in a phase II study imatinib 
exhibited high incidence of complete cytogenetic remission in chronic phase 
patients that had previously failed interferon α161. Imatinib became the first 
line treatment for CML patients following the IRIS study162, which compared 
imatinib vs. low dose cytarabine and interferon α in newly diagnosed patients. 
Imatinib has since revolutionized treatment, management and outcome of the 
disease and has served as an exemplar for molecularly targeted agents for 
cancer therapy. In less than 10 years, the prognosis of the disease has 
improved from deadly to 80-90% of patients being alive at 10 years163.  
 
The anti-leukemia effect of imatinib is achieved by competitive inhibition of the 
ATP binding site in the kinase domain of ABL1, thus blocking BCR-ABL1 
authophosphorylation164. Imatinib is able to bind to the ABL1 kinase domain 
only when the conformation of activation loop of the kinase is in an inactive 
state (DFG-out)165. Besides ABL1, imatinib also potently inhibits KIT, colony-
stimulating factor-1 receptor (CSF1R), and platelet derived growth factor 
receptor (PDGFR) α and β166. The five year follow up of the IRIS study 
showed that complete hematologic response (normalization of blood cell 
counts), major cytogenetic response (0-35% of Ph+ metaphases), and 
complete cytogenetic response (0% Ph+ metaphases) was achieved in 98%, 
92%, and 87% of imatinib treated patients, respectively167. Moreover, 8-year 
follow up revealed that event and progression free survival in patients treated 
with imatinib was 81% and 92%, respectively168. More recent data have 
demonstrated that acquisition of deeper molecular responses over time is 
strongly associated with progression-free survival169 and BCR-ABL1 transcript 
levels of less than 10% at 3 months forecasts for complete cytogenetic 
response, overall and progression-free survival170. Imatinib is generally well 
tolerated and the most common side effects include myelosuppression, 
edema, nausea, diarrhea, headaches, itchy rash, and myalgia142. 
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5.3 Imatinib resistance 
 
Although treatment with imatinib leads to high response rates, still 
approximately one third of patients require alternative therapy due to primary 
resistance (lack of efficacy), acquired resistance (loss of efficacy) and/or 
intolerance. Several resistance mechanisms have been recognized such as 
BCR-ABL1 amplification, overexpression of the multidrug resistant P-
glycoprotein, minimal activity of the drug influx transporter OCT1, and the 
occurrence of point mutations in the ABL1 kinase domain171-174. The 
manifestation of point mutations is the most common resistance mechanism, 
which interferes with the inhibitor-binding site or leads to stabilization of BCR-
ABL1 in a conformation with lower binding affinity for imatinib. Point mutations 
in the kinase domain were initially identified in 11 patients with advance phase 
disease resistant to imatinib173. In six of those patients, the same threonine to 
isoleucine amino acid substitution at position 315 was detected, known as the 
T315I gatekeeper mutation (Figure 10). Since then, over 100 different 
nucleotide changes have been reported with 15 amino acid substitutions 
accounting for more than 85% of mutations seen in the clinic141. Imatinib 
resistance led to the development of second and third generation ABL1 
specific inhibitors, each with diverse potency, specificity and mutation 
coverage spectra. Currently there are four different ABL1 TKIs on the market 
in addition to imatinib: dasatinib, nilotinib, bosutinib and ponatinib. The T315I 
mutation occurs in 20% of relapsed and refractory patients and confers 
resistance to all approved BCR-ABL1 inhibitors, except ponatinib. Even 
though the T315I mutation does not destabilize the overall structure of BCR-
ABL1, it has an effect on the topology of the ATP binding side175. Lack of 
efficacy of first and second-generation inhibitors in this setting occurs due to 
either elimination of the hydroxyl group critical for hydrogen bonding with the 
isoleucine substitution or steric hindrance that prevents TKI binding to the 
hydrophobic pocket whilst allowing access to ATP175-177. 
 
 
 
Figure 10. Graphical representation of the threonine to isoleucine substitution at 
residue 315 preventing imatinib to bind to the ATP binding pocket of ABL1. This 
amino acid change removes a vital oxygen molecule required for hydrogen bonding 
between imatinib and ABL1. Adapted from Tanaka and Kimura, Expert Rev 
Anticancer Ther, 2008178. 
T315I
Critical for hydrogen
bonding
Threonine 315 Isoleucine 315
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5.4 Dasatinib 
 
Dasatinib, developed by Bristol-Myers Squibb, was the first second generation 
TKI to exhibit clinical efficacy in imatinib resistant patients179-181. Preclinical 
evaluation showed that dasatinib is 300-fold more potent than imatinib and 
has inhibitory efficacy against majority of imatinib resistant mutations with 
noteworthy exception of T315I182,183. Besides T315I, dasatinib has lack of 
activity towards F317V/L, T315A and V299L. In contrast to imatinib, dasatinib 
can bind to ABL1 when the kinase domain is in an active (DFG-in) or inactive 
conformation with preference for the active state of the kinase184. This feature 
of dasatinib poses less stringent binding requirements making it less 
amenable to mutational escape185. In addition to ABL1, dasatinib has potent 
activity towards SRC family kinases, KIT, ephrin receptors, PDGFR-β, among 
others. Dasatinib was initially approved for CML and Ph+ ALL patients 
resistant or intolerant to prior therapy including imatinib, but has since been 
approved for first line treatment of chronic phase CML patients. The most 
frequently occurring side effects are myelosuppression, pleural effusions, 
intracranial bleed, QT prolongation, diarrhea, and headache142. 
 
5.5 Nilotinib 
 
Nilotinib was rationally designed by Novartis to structurally resemble imatinib 
with improvements in binding affinity, ABL1 selectivity and potency183. 
Therefore, nilotinib is approximately 30-fold more potent than imatinib. 
Similarly to imatinib, nilotinib binds ABL1 in its inactive conformation, but its 
superior topographic fit contributes to its mutation coverage186,187. In line with 
dasatinib, nilotinib has activity against most imatinib resistant mutations with 
the exception of T315I, E225K/V and Y253H188,189. Moreover, nilotinib has 
inhibitory activity against PDGFR, KIT, DDR1, and ephrin receptors. Clinical 
efficacy of nilotinib was initially demonstrated in imatinib resistant or intolerant 
patients190-192, which led to regulatory approval for CML patients in chronic or 
accelerated phase refractory to prior therapy. Nilotinib has since also been 
approved for newly diagnosed chronic phase CML patients. The most 
common side effects of nilotinib are skin rashes, electrolyte imbalance, 
hyperglycemia, pancreatitis, myelosuppression, fatigue, diarrhea and 
headache142.  
 
6.6 Bosutinib    
 
Bosutinib, developed by Pfizer, is a dual ABL1/SRC orally available second 
generation inhibitor with activity against most imatinib resistant mutants 
excluding T315I and V299L. Intriguingly, bosutinib has the ability to bind ABL1 
in both its active and inactive conformations193. Bosutinib is currently 
approved for CML patients resistant or intolerant to previous therapy as it 
exhibited efficacy in patients who have lost sensitivity to imatinib, nilotinib and 
dasatinib194,195. Main adverse events of bosutinib treatment are diarrhea and 
hepatotoxicity, but myelosuppression, nausea, vomiting and skin rashes can 
also occur142. 
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6.7 Ponatinib 
 
The third generation inhibitor ponatinib was rationally designed to overcome 
the limitations of second-generation inhibitors in targeting the BCR-
ABL1(T315I) mutation196. Hence, ponatinib is the only clinically available 
inhibitor to display efficacy against the T315I mutation in addition to most 
imatinib-resistant mutants197,198. Interestingly, a recent study reported that the 
T315M mutation derived from T315I is associated with high-level ponatinib 
resistance199. Ponatinib binds ABL1 in its inactive conformation and its 
structure is characterized by a unique triple bond ethynyl linker that effectively 
overcomes the steric hindrance otherwise caused by I315. Ponatinib is potent 
inhibitor of a number of other kinases such as VEGFR, PDGFR, FGFR, SRC, 
KIT, RET and FLT3197. Following the pivotal phase II (PACE) trial200, ponatinib 
obtained regulatory approval under the FDA’s accelerated approval program 
for CML and Ph+ ALL patients resistant or intolerant to prior tyrosine kinase 
inhibitor treatment. Responses to ponatinib are durable in chronic phase CML, 
but typically transient in blast phase CML and Ph+ ALL200. In addition, during 
the EPIC, phase III, trial high incidence of life-threatening blood clots and 
severe narrowing of blood vessels was observed that led the FDA to suspend 
the trial and temporarily withdraw ponatinib from the market201,202. These side 
effects most likely result due to ponatinib’s potent nature and pan-activity203. 
The drug has since been reinstated for a narrower patient population (adults 
with CML and Ph+ ALL with T315I mutations or CML and Ph+ ALL patients 
ineligible for other TKI) with a black box warning204. 
 
5.8 Sequential TKI treatment and resistance 
 
Newly diagnosed CML patients have the possibility of starting treatment with 
any of the frontline approved drugs (e.g. imatinib, dasatinib or nilotinib). 
However, evidence has shown that over 30% of patients will require 
alternative treatment due to resistance or intolerance of first line TKI205. 
Primary resistance likely occurs due to the presence of kinase domain 
mutations at baseline. On the other hand, secondary resistance is the result of 
selection of resistant clones from prolonged exposure to TKIs, which is 
supported by the observation that sequential TKI treatment frequently 
promotes greater TKI resistance206,207. Kinase domain mutations contributing 
to drug resistance generally occur at strategic positions (e.g. ATP-binding and 
activation loops), which block inhibitor binding while maintaining ATP binding 
ability and kinase activity208. Though, some mutations are known to reduce 
the inherent kinase activity such as the M351T mutation209. Mutations can 
occur in the kinase active site resulting in steric hindrance and at positions 
that either influence the overall structure of the kinase or preclude the 
adoption of the inactive state203.  
 
Previous research has shown that sequential TKI treatment also leads to the 
development of multiple mutations in the ABL1 kinase domain, which can 
either be compound (multiple mutations in the same BCR-ABL1 molecule) or 
polyclonal (multiple mutations occurring in several BCR-ABL1 
molecules)207,210. In a recent study of 1,700 patient samples, multiple 
mutations were detected in 11.4% of the cases with 70.2% accounting for 
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compound and 29.8% for polyclonal mutations189. Majority of compound 
mutations consisted of two mutations (76%) in comparison to triple (21%) and 
quadruple (3%) mutations. The composition of the compound mutations was 
in line with TKI treatment history with one or more mutational partners linked 
with the typical clinical resistance profile of the particular TKI189. In addition, 
two other studies have identified compound and polyclonal mutations that 
confer clinical resistance to ponatinib with T315I-comprising compound 
mutants resulting in enhanced resistance to all clinically available TKIs, 
including ponatinib199,211. Interestingly, the compound mutations displayed 
several-fold higher resistance profile than either of the mutations alone. 
Moreover, most compound mutations detected in patients so far consist of key 
single mutations, indicating that there is a restricted number of catalytically 
sustainable combinations199. Nevertheless, the development of complex 
polymutants represents a novel escape route for resistant clones, warranting 
robust sequencing methods and rational treatment selection to boost the 
clinical outcome of Ph+ patients. 
 
6. Ph+ ALL 
 
Even though BCR-ABL1 is sufficient for CML initiation, additional genetic 
aberrations or transforming events are required for development of Ph+ ALL. 
Activation of SRC family of kinases212, deletions in IKZF1 (IKAROS)213-216 and 
CDKN2A/B203,204, and deletions, fusions or amplifications in PAX5217-220 have 
all been implicated in Ph+ ALL pathogenesis. Ph+ ALL is derived from 
expansion of immature lymphoid lineage cells. However, a functional study 
has shown that both CML and Ph+ ALL arise from common cells of origin 
resembling long-term hematopoietic stem cells (LT-HSCs)	  221. In addition, the 
study showed that the difference among the disease states occurs during 
disease-maintenance where STAT5 signaling is essential for CML 
transformation while IL-7 signaling is critical for LT-HSCs differentiation to pro-
B cells and consequent Ph+ ALL initiation221. 
 
In most Ph+ ALL patients the 190 kDa BCR-ABL1 is expressed, whereas the 
rest harbor the 210 kDa variant. Several other differences exist between CML 
and Ph+ ALL at the clinical and molecular level. For instance, the presence of 
the Philadelphia chromosome is an adverse prognostic factor in ALL, which is 
not the case in CML. Moreover, Ph+ ALL is characterized with additional 
epigenetic modifications, copy number alterations, and mutations downstream 
of BCR-ABL1 that play a role in the aggressive clinical course of the disease, 
which may include involvement of the central nervous system (CNS). 
Therefore, preventing leukemia cell growth is not accomplished by merely 
inhibiting BCR-ABL1222.  
 
Historically, patients have been treated with aggressive chemotherapy 
regimens and complete response rates were achieved in 45%-90% of 
patients. Nevertheless, majority of patients relapse and only few achieve long-
term survival. The only curative treatment is allogeneic HSCT for eligible 
patients (donor is found and patient is able to tolerate the procedure), 
although relapse following HSCT and treatment-related mortality are not 
uncommon223,224. Nowadays, imatinib has been incorporated into first-line 
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regimens as its use improves the outcome of Ph+ ALL patients. However, 
imatinib treatment is susceptible to resistance in this setting as well225,226. 
Dasatinib has been approved as a second-line therapy for Ph+ ALL patients 
resistant or intolerant to prior therapy, including imatinib. Despite its clinical 
efficacy, the inhibitory effect against SRK family of kinases227 and improved 
CNS penetration228 than imatinib make it an attractive alternative. In addition 
to imatinib and dasatinib, ponatinib has regulatory approval as second or third 
line treatment in patients with Ph+ ALL. Nonetheless, allogeneic HSCT in first 
complete response should be contemplated for eligible patients224. 
 
7. Drug sensitivity testing of cancer cells 
 
For a number of decades, efforts have been directed towards developing 
technologies that directly assess the sensitivity of patient cancer cells to drugs 
in vitro229,230. However, success in predicting cancer cell chemosensitivity in a 
clinical setting has been limited, as most studies have focused on 
conventional chemotherapeutics231-234, responses to which are frequently 
unselective, challenging to decipher and translate to patient care. More and 
more evidence is accumulating that kinases are frequently deregulated in 
human cancers, including leukemias, prompting excitement for kinase specific 
inhibitors. Therefore, unbiased phenotypic cancer drug sensitivity studies 
focusing on targeted agents hold promise for identification of links between 
drug responses and genetic and clinical features. For example one such study 
reported that 70% of leukemia patient samples display hypersensitivity to one 
or more kinase inhibitors235, illustrating that this approach can serve as means 
to discern cancer kinase pathway dependencies and molecular markers of 
drug response.  
 
Besides drug efficacy testing in primary cancer cells, many more studies have 
been conducted on human cancer cell lines that might not always fully 
recapitulate the heterogeneity and genomic complexity of human cancers. 
One of the first cancer cell line screening programs was the National Cancer 
Institute 60 (NCI60) platform236, covering 60 different cell lines representing 
nine different cancer histopathological types. The NCI60 platform developed 
technologies that are the foundation of numerous drug screening programs 
today, but the weakness of using only 60 cell lines in terms of capturing tumor 
heterogeneity, genetic diversity and low-frequency responders has become 
more evident lately237. Recent efforts such as the Cancer Cell Line 
Encyclopedia (CCLE)238 and Cancer Genome Project (CGP)239 have focused 
on characterizing the drug sensitivity profiles of several hundred human 
cancer cell lines (947 cell lines covering 36 tumor types and 24 drugs, and 
727 cell lines 16 tumor types and 138 drugs, respectively). In addition to drug 
sensitivity profiles, the studies generated genomic profiles of the cell lines that 
facilitated the identification of genetic, lineage, and gene-expression 
biomarkers of drug sensitivity. However, these studies revealed very few 
novel drug sensitivity-biomarker links, possibly due to each cancer type being 
represented by a handful of cell lines that might not be sufficient to 
comprehensively detect disease subgroup-specific associations. Nonetheless, 
high-throughput drug sensitivity testing of cancer cell lines can be an 
attractive approach to identify novel drug-target links and cancer subtypes 
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that might benefit from a particular drug. However, results still need to be 
verified and explored in either patient samples or proof of concept clinical 
trials, as cell lines do not fully resemble the disease manifestation in patients. 
Therefore, more biologically and clinically relevant data might be obtained 
from studying cancer patient samples that encompass not only the genetic 
complexity, but also intricate signaling networks that drive cancer progression 
and influence response to therapy. 
 
The pharmacogenomics field has been criticized recently, as comparative 
analyses of CCLE and CGP data found discrepancies in the drug sensitivities 
reported albeit no large differences in gene expression profiles240,241. These 
findings shed doubt on the value of drug screening of cancer cell lines as 
means of developing predictive markers of drug response. The observed 
differences likely stem from no standardized experimental protocols in terms 
of cell handling, drug concentration ranges, readouts, and modeling and 
scoring of dose response curves (Table 4)240,242. In contrast, higher degree of 
accordance was detected when comparing CCLE and GlaxoSmithKline 
(GSK)243 data on lapatinib and paclitaxel sensitivity as both studies utilized the 
same readout (ATP production as a measure of cell viability)240. This suggests 
that the assay has significant impact on the quantification of the drug 
response. Moreover several other factors can influence experiment outcomes: 
cell culture conditions, cell line genetic deviation due to passaging, compound 
handling and storage, and assay conditions. For instance, comparison of 
different readouts has revealed that ATP-based luminescent assays while 
very sensitive are susceptible to underestimation of drug potency and 
efficacy, especially for compounds interfering with DNA synthesis244.  
 
Primary data outputs of high-throughput drug screening studies are 
compound dose response curves and associated drug response measures 
such as half-maximal inhibitory concentration (IC50) and area under the curve 
(AUC). Since no standard drug response metric has been established, most 
commonly the IC50 is used to evaluate drug sensitivity that has limitations in 
fully capturing the drug response information. Both, AUC and IC50, 
estimations depend on drug-cell line/type pair, shape of the curve and drug 
concentration range tested. In addition, heterogeneous cell populations and 
intrinsic cellular variability might significantly affect the cumulative drug 
response measured242,245. Intriguingly, certain compounds in the CCLE study 
could be classified as effective or ineffective depending on which metric is 
used for analysis241. Thus, development of novel scoring methods that can 
capture the qualitative and quantitative drug sensitivity information are 
needed. 
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Table 4. Differences and similarities in experimental protocols used in CCLE and 
CGP studies 
 CCLE CGP 
Cell lines Commercial vendors, COSMIC annotated 
Commercial vendors, 
COSMIC annotated 
Culture medium RPMI or DMEM + 10% FBS 
RPMI or DMEM + 5% FBS 
+ penicillin/steptomycin 
Cell seeding density N/A 70% cell confluence 
Compound storage 90% DMSO, 10% water at 2 mM (-20°C) 10 mM aliquots (-80°C) 
Cell plating 1536 plates (5 µl final volume 250 cells/well) 96- or 384-well plates 
Drug concentration Serial dilutions (2 mM to 636 nM) 
The range of 
concentrations for each 
compound is based on 
prior in vitro data 
Adherent cells 
Plated 12-48 h prior to 
compound addition after 
which 72-84 h incubation 
Plated 1 day prior 
compound addition after 
which 72 h incubation 
Suspension cells N/A 
Immediately treated with 
compounds and incubated 
for 72 h 
Viability measurement ATP based (CellTiter Glo; Promega) 
Resazurin based (Sigma) 
or florescent nucleic acid 
stain Syto60 (Invitrogen) 
Controls Negative: Vehicle only cells Positive: MG132 
Negative: 8 (96-well) or 32 
(384) no cells wells 
Positive: 16 (96) or 42 
(384) drug-free wells 
Assay reproducibility 
Compounds tested in 
duplicate, some cell lines 
assayed several time at 
different time points (data 
not shown) 
Assays performed at two 
different sites with matched 
cell collections (data 
shown for 3 drugs only) 
Drug response curve fit 
Decision tree methodology 
(NIH/NCGC assay 
guidelines) 
Bayesian sigmoid model 
Drug sensitivity 
statistic EC50, IC50, AUC, Amax IC25, IC50, IC75, IC90, AUC 
In CGP resazurin was used for detecting cell viability in suspension cells, whereas, 
Syto60 for adherent cells that detects total cell counts. AUC-area under the curve; 
COSMIC-catalogue of somatic mutations in cancer; DMSO-dimethyl sulfoxide; FBS-
fetal bovine serum; MG132-proteasome inhibitor effectively killing all cells at 1 µM;. 
Adapted from Hatzis et al, Cancer Res, 2014242. 
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AIMS OF THE STUDY 
 
The overall aim of this doctoral dissertation was to functionally profile 
leukemia patient cells in terms of molecular vulnerabilities with a drug 
sensitivity and resistance testing platform in order to identify personalized 
therapy options. 
 
1. Development and implementation of a predictive in vitro and ex 
vivo (high-throughput) drug sensitivity and resistance testing 
platform for personalized cancer medicine applications for leukemia 
patient samples 
 
2. Development of a score to quantify drug sensitivity and 
resistance 
 
3. Understanding and identification of molecular drivers of AML 
using drug screening data 
 
4. Identification of drug repurposing opportunities for leukemia 
patients  
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MATERIALS AND METHODS 
 
8. Study specimens 
 
8.1 Patients 
 
AML, CML and Ph+ ALL patients studied in projects I-II and Supplementary 
article (SA) I were clinically diagnosed based on FAB or WHO criteria10. 
Samples from these patients were primarily collected at Helsinki University 
Hospital Comprehensive Cancer Center, Department of Hematology after 
written informed consent and ethical approval of the Institutional Review 
Board of the Hospital (No. 239/13/00/2010, 303/13/03/01/2011). The consent 
form also included the possibility to use DSRT data to guide therapies with 
approved drugs in an off-label mode in accordance with Finnish legislation. In 
addition, the studies were performed in agreement with Declaration of 
Helsinki. Specimens from healthy individuals were collected in an outpatient 
clinic setting with informed consent. Only freshly processed samples were 
included in all studies. 
 
Study I evaluated the drug sensitivity and molecular profiles of 28 bone 
marrow samples from 18 AML and high-risk MDS patients. In addition, 7 bone 
marrow samples from healthy individuals were analyzed as controls. Nine 
samples were collected from newly diagnosed patients, whereas 19 from 
relapsed and/or refractory patients. Skin biopsies from the AML and MDS 
patients were used as germline controls for exome sequencing data. Study II 
identified and characterized the tyrosine kinase inhibitor axitinib as a putative 
novel inhibitor of BCR-ABL1(T315I). For this purpose drug sensitivity profiles 
of samples derived from 3 CML in blast crisis, 3 Ph+ ALL, 33 AML patients, 
and 7 healthy donors were compared. Four out of 6 Ph+ samples harbored 
the T315I mutation. Majority of AML samples included in this study were 
previously analyzed in study I. SA I incorporated a slightly overlapping cohort 
with study I and utilized 22 and 4 bone marrow aspirates from 14 primarily 
relapsed and refractory AML patients and 4 healthy donors, respectively. Four 
samples (from 4 different patients) were not included in study I. Eight samples 
were obtained from newly diagnosed patients and the remaining 14 from 
relapsed and/or refractory patients. 
 
8.2 Sample processing and handling 
 
Bone marrow or peripheral blood aspirates from leukemia patients were 
subjected to Ficoll centrifugation (Ficoll-Paque PREMIUM; GE Healthcare) in 
order to isolate the mononuclear cells according to manufacturer’s 
instructions. Mononuclear cells were washed, counted, and maintained in 
mononuclear cell medium (MCM; PromoCell) containing 0.5 µg/ml gentamicin 
and 2.5 µg/ml amphotericin B. In study I, one sample from a secondary AML 
patient, was further separated based on CD34 positivity status with magnetic 
beads according to manufacturer’s instructions (Miltenyi Biotech). If there 
were excess cells available, they were either stored as pellets at -70 or 
biobanked in liquid nitrogen in FBS and 10% DMSO for future use. 
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8.3 Cell lines 
 
Besides patient material, study II and SA I utilized cell line material as well. 
Engineered Ba/F3 cells analyzed in study II were attained from Oregon Health 
and Science University and cultured in RPMI-1640 supplemented with 10% 
FBS and 1% penicillin/streptomycin. To further illustrate the applicability of the 
drug sensitivity score, SA I also used publicly available human cancer-cell line 
drug sensitivity data from the CCLE238 resource (479 cell lines tested against 
24 oncology compounds).  
 
9. Inhibitors 
 
The oncology compound collection was composed of commercially available 
approved, investigational and experimental anti-cancer compounds. The 
collection included most US Food and Drug Administration/European 
Medicines Agency (FDA/EMA) approved oncology drugs and covered a wide 
array of molecular targets (Table 5). Inhibitors were dissolved in DMSO or 
water and stored in desiccators according to manufacturer’s instructions. 
Hundred eighty-seven, 252, and 204 anti-cancer agents were used in study I, 
II and SA I, respectively. Compounds were acquired from National Cancer 
Institute Drug Testing Program or purchased from: Active Biochem, Axon 
Medchem, Cayman Chemical Company, ChemieTek, Enzo Life Sciences, LC 
Laboratories, Santa Cruz Biotechnology, Selleck, Sequoia Research 
Products, Sigma-Aldrich, and Tocris Biosciences. 
 
9.1 Drug sensitivity and resistance testing (DSRT) 
 
DSRT was conducted on freshly isolated primary mononuclear cells derived 
from patients or healthy donors. Compounds were preprinted on tissue culture 
treated 384-well plates (Corning 3707) with an acoustic liquid handling device 
(Echo 550; Labcyte Inc.). Each compound was dispensed in five different 
concentrations (10-fold dilutions) covering a 10,000-fold concentration range 
(e.g. 1-10,000 nM). Ready-made plates were stored until needed in nitrogen 
pressurized StoragePods (Roylan Developments Ltd.). Prior to cell addition, 
compounds were suspended in 5 µl MCM and the plates placed on a shaker 
for 30 minutes. Single cell suspension of mononuclear cells (10,000 cells/well 
in 20 µl) was then transferred to every well with a MultiDrop Combi (Thermo 
Scientific) peristaltic dispenser. The microtiter plates were then incubated for 
72 h at 37°C and 5% CO2. Following the 72 h incubation, cell viability was 
measured using the CellTiter Glo luminescent assay (Promega) according to 
manufacturer’s instructions with either Molecular Devices Paradigm or BMG 
Labtech PHERAstar plate readers. Sixteen positive (100 µM benzethonium 
chloride containing wells) and 16 negative (DMSO only) control wells were 
included on each plate for data normalization. Dotmatics Browser/Studies 
software (Dotmatics Ltd.) was used for percentage of survival calculation and 
dose response curve generation for each drug tested. A four-parameter 
logistic fit function was used to model the dose response curve defined by 
minimum and maximum inhibition, slope and the inflection point (IC50/EC50) 
with the top asymptote fixed to 100 and bottom asymptote floating between 
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0% and 75%. Hence, compounds exhibiting less than 25% inhibition were 
pondered inactive. 
 
Table 5. Compounds and drug classes included in the DSRT platform 
Drug class Compounds 
Apoptotic 
modulators AT 101, navitoclax, nutlin-3, obatoclax, serdementan, YM155 
Conventional 
chemotherapeutics 
ABT-751, allopurinol, altretamine, amonafide, auranofin, 
bendamustine, bleomycin, bortezomib, busulfan, camptothecin, 
capecitabine, carboplatin, carfilzomib, carmustine, chlorambucil, 
chloroquine, cladribine, clofarabine, cyclophosphamide, cytarabine, 
dacarbazine, dactinomycin, daunorubicin, docetaxel, doxorubicin, 
etoposide, floxuridine, fludarabine, fluorouracil, gemcitabine, 
hydroxyurea, idarubicin, ifosfamide, indibulin, irinotecan, 
ixabepilone, lomustine, melphalan, mercaptopurine, mitomycin C, 
mitotane, mitoxantrone, nelarabine, omacetaxine, paclitaxel, 
patupilone, pentostatin, pipobroman, plicamycin, procarbazine, 
streptozocin, temozolomide, teniposide, thioTEPA, thioguanine, 
topotecan, uracil mustard, valrubicin, vinblastine, vincristine, 
vinorelbine 
Differentiating/ 
epigenetic modifiers 
 
(+)JQ1, arsenic (III) oxide, azacitidine, belinostat, bexarotene, 
CUDC-907, decitabine, entinostat, iniparib, mocetinostat, niraparib, 
olaparib, panobinostat, PFI-1, quisinostat, rucaparib, stemregenin 1, 
tacedinaline, tipifarnib, tretinoin, tubacin, tubastatin A, valproic acid, 
veliparib, vorinostat, XAV-939 
Hormone therapies 
4-hydroxytamoxifen, abiraterone, aminoglutethimide, anastrozole, 
bicalutamide, clomifene, enzalutamide, exemestane, finasteride, 
flutamide, fulvestant, goserelin, lasofoxifene, letrozole, megestrol, 
nilutamide, raloxifene, RD162, tamoxifen, toremifene 
HSP inhibitors alvespimycin, BIIB021, geldanamycin, luminespib, tanspimycin, VER 155008 
Immunomodulatory 
agents 
bimatoprost, celecoxib, dexamethasone, imiquimod, lenalidomide, 
levamisole, methylprednisolone, prednisolone, prednisone, 
thalidomide 
Kinase inhibitors 
afatinib, alisertib, alvocidib, apitolisib, AT9283, axitinib, AZ 3146, 
AZD1152-HQPA, AZD1480, AZD4547, AZD7762, AZD8055, BI 
2536, binimetinib, BMS-754807, brivanib, bryostatin 1, buparlisib, 
cabozantinib, canertinib, cediranib, crizotinib, CUDC-101, dactolisib, 
danusertib, dasatinib, doramapimod, dovitinib, EMD1214063, 
enzastaurin, erlotinib, fasudil, foretinib, fostamatinib, galunisertib, 
gandotinib, gefitinib, ibrutinib, idelalisib, imatinib, INK128, KX2-391, 
lapatinib, lestaurtinib, linifanib, linsitinib, masitinib, MGCD-265, 
midostaurin, MK-2206, MK-1775, momelotinib, motesanib, neratinib, 
nilotinib, nintedanib, NVP-BGJ398, omipalisib, OSI-027, palbociclib, 
pazotinib, perifosine, PF-00477736, PF-04691502, PF-04708671, 
pictilisib, PIK-75, pilaralisib, pimasertib, ponatinib, quizartinib, 
rabusertib, RAF265, refametinib, regorafenib, ruboxistaurin, 
ruxolitinib, saracatinib, seliciclib, selumetinib, SNS-032, sonolisib, 
sorafenib, sotrastaurin, sunitinib, TAK-733, TAK-901, tamatinib, 
tandutinib, TGX-221, tivantinib, tivozanib, tofacitinib, trametinib, 
UCN-01, vandetanib, vatalanib, vemurafenib, volasertib, voxatalisib, 
VX-11E 
Kinesin inhibitors SB 743921, S-trityl-L-cysteine 
Metabolic modifiers atrovastatin, daporinad, methotrexate, pemetrexed 
Rapalogs everolimus, ridaforolimus, sirolimus, tacrolimus, temsirolimus 
Other 
15D-PGJ2, 2-methoxyestradiol, anagrelide, erismodegib, fingolimod, 
galiellalactone, MK-0752, PF-3845, pilocarpine, plerixafor, Prima-1 
Met, tarenflurbil, tosedostat, varespladib, vismodegib 
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9.2 Drug sensitivity score (DSS) 
 
In order to quantify the drug sensitivity data and compare the observed drug 
responses in different patient samples, a single measure termed drug 
sensitivity score (DSS) was developed. The DSS takes into account all four 
curve-fitting parameters, which are used to calculate the AUC in relation to the 
total area between 10% threshold and 100% inhibition (Figure 11). The score 
is further normalized by the logarithm of the top asymptote to reduce the 
impact of toxic drug effects (effect of maximal response at highest tested 
concentration). The default curve fitting function used in these studies is 
depicted below where 𝑎 is top asymptote (max response), 𝑏 the slope, 𝑐 the 
IC50 and 𝑑 the bottom asymptote (min response): 
 𝑦 = 𝑑 + 𝑎 − 𝑑1+ 10!(!!!) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Graphical illustration of the drug sensitivity score calculation. Courtesy of 
Bhagwan Yadav.  
 
DSS is 0 in cases where the maximum response is 10% or lower or IC50 
equals or is beyond the maximum drug concentration tested. The possible 
range of DSS values is between 0 and 50. To identify cancer selective drug 
responses the DSS values detected in patient samples to ones detected in 
healthy bone marrow control samples were compared (selective DSS; sDSS). 
In study I, sDSSs were also utilized to uncover similarities and differences of 
drug sensitivity profiles and functionally group patient samples and drugs with 
data clustering analysis (complete-linkage method and Spearman (drugs) and 
Euclidean (samples) distance measures). In SA I, clustering of drug 
responses was done with the Ward’s algorithm using Spearman (drugs) and 
Manhattan (samples) distance measures. The DSS-based data analysis 
platform is freely available as an R-package at: 
https://dss-calculation.googlecode.com/svn/trunk/). 
 
 
),,,,(d)(
)(
TdcbafxxyAUC
Txy
== ∫
≥
DSS = AUCTotalArea ×100
"
#
$
%
&
'
/ log10 (a)
	   42	  
9.3 Kinase addiction prediction 
 
In order to identify kinase signaling networks involved in disease 
pathogenesis in the AML patient samples incorporated in study I and SA I, the 
sDSS data of kinase inhibitors was used. The goal was to predict sample-
specific kinase addictions by relating patient sample-specific sDSS responses 
to target specificity data of 35 kinase inhibitors (overlapping between the 
studies) derived from a recent comprehensive kinase inhibitor selectivity 
study246. With this data a kinase inhibition sensitivity score (KISS) was 
developed that predicts how amenable the patient cells are to inhibition of a 
particular kinase. The KISS entails calculating the mean sDSSs of those 
agents selectively targeting a kinase of interest. To refine the obtained results, 
gene expression data was correlated with the candidate kinase addictions to 
eliminate nonexpressed targets. The expressed kinases were then used to 
characterize a putative ‘kinaddictome’ for a particular patient sample and 
determine the kinase pathway dependence. KISS data was visualized with 
automated layout options in the Cytoscape software247. 
 
9.4 CCLE drug screening approach and data 
 
In the CCLE study each compound was tested in 8 different concentrations 
(2.5, 8, 25, 80, 250, 800, 2,530, and 8,000 nM). Since technical replicate data 
was available, in SA I DSS was calculated for the median dose response 
data. For comparative analysis of our AML patient sample drug screening 
data the DSS as well as Activity Area238 (AA; metric used in CCLE) 
calculations were implemented. AA takes into account the difference between 
the measured response (relative growth inhibition %) and reference response 
(response set to 0) over eight concentrations. Hence, AA is 0 when no drug 
efficacy is observed and 8 when there is 100% inhibition at all 8 drug 
concentrations.  
 
9.5 Engineered Ba/F3 cell proliferation assays 
  
In study II to illustrate that axitinib specifically inhibits BCR-ABL1(T315I) in 
cells, Ba/F3 transformed to express BCR-ABL1 or BCR-ABL1(T315I) were 
utilized. Engineered Ba/F3 cells were maintained in RPMI-1640 with 1% FBS 
and 1% penicillin/streptomycin and seeded in 96-well flat bottom plates at 
1,500 cells/well. Imatinib, ponatinib and axitinib were initially dissolved in 
DMSO to make 10 mM stocks, then 3-fold serial diluted in DMSO in 96-well 
plates after which 40-fold diluted in complete media to generate a 5X source 
plate. Twenty-five µl of compound suspension (per well) from the 5X source 
plate was transferred to the cells containing assay plate and the assay plates 
were incubated for 96 h at 37°C and 5% CO2. Prior to reagent addition, 80 µl 
of supernatant was removed from each assay plate well, following a brief 
centrifugation step, and the cells were resuspended with 100 µl of fresh 
medium. Cell viability was measured after 6 h incubation with resazurin (15 
µl/well of 1 mg/ml; Sigma) at 530 nm excitation and 595 nm emission 
wavelengths.  
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To evaluate axitinib’s ability to inhibit the growth of a wider panel of 
engineered Ba/F3 cells, cells were dispensed in 96-well round bottom plates 
at concentration of 10,000 cells/well in RPMI-1640 and 10% FBS and 
increasing concentrations of axitinib (0-10,000 nM). Cells were incubated with 
drug for 72 h and cell viability was measured with the tritiated thymidine 
incorporation assay as previously reported by le Coutre and collegues248. 
Data was analyzed with GraphPad Prism software. 
 
10. DNA and RNA isolation 
 
DNA was isolated from bone marrow or peripheral blood mononuclear cells 
and skin cells with the DNeasy Blood & Tissue Kit (Quigen). RNA was 
extracted with miRNeasy Kit (Qiagen). Concentration of DNA and RNA were 
quantified with Nanodrop (Thermo Fischer), Qubit 2.0 (Life Technologies), or 
Agilent 2100 bioanalyzer (Agilent Technologies). 
 
10.1 DNA sequencing 
 
In study I exome sequencing was performed on 20 and in SA I on 12 AML 
patients samples. Moreover, whole genome sequencing was done on skin 
and AML cells derived from sample 784_2. Approximately 3 µg of DNA was 
fragmented and prepared according to the NEBNext DNA Sample Prep 
Master Mix protocol (New England Biolabs). The Nimblegen SeqCap EZ v2 
capture Kit (Roche NimbleGen) was used for exome capture. DNA 
sequencing (exomes and genomes) was done with Illumina HiSeq 1500, 2000 
or 2500 instruments (Illumina). Forty million base pair paired-end reads were 
sequenced from each germline control sample and 100 million for each tumor 
sample. DNA isolated from the leukemic cells of patient 1497 was sequenced 
on the MiSeq sequencer (Illumina) with the Illumina TruSeq Amplicon Cancer 
Panel. The sequence data was then processed with bioinformatics analysis 
pipelines as previously described249,250. Cancer somatic mutations were called 
with the VarScan2 somatic mutation caller251. Data annotation was performed 
with SnpEff (Ensembl v60 annotation database)252, while filtering with 
RepeatMasker track (University of California, Santa Cruz genome browser) 
and Single Nucleotide Polymorphism database for false-positive calls due to 
genomic repeats and misclassified germline variants. Candidate mutations 
were further visually verified with the Integrated Genomics Browser (Broad 
Institute). Variant allele frequencies were used to inspect not high-confidence 
mutation calls and identify regions of loss of heterozygosity.  
 
10.2 Capillary sequencing 
 
Capillary sequencing was used to determine FLT3-ITD mutational status of 
AML patient samples. Isolated genomic DNA was amplified by qualitative 
PCR as per Kottaridis et al253 using a 6-carboxyfluorescein-labeled forward 
primer. PCR products were size-separated on agarose gel and by capillary 
electrophoresis using an ABI3500Dx Genetic Analyzer and sequenced via 
M13-tailed direct sequencing. Minimal residual disease level analysis was 
performed with real-time quantitative PCR (RT-PCR). Albumin gene levels 
were used to normalize the RT-PCR data.  
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10.3 Amplicon sequencing 
 
Somatic mutation data in study I was verified by amplicon sequencing with 
locus-specific PCR primers containing Illumina compatible adapter and 
grafting sequences and an amplicon specific index sequence (6 base pairs). 
For the PCR reaction, 10 ng of DNA were combined with 10 µl 2x Phusion 
High-Fidelity PCR Master Mix (Thermo Scientific) and 0.5 µM of each primer. 
Primer sequences are provided in Table 6. Sample purification was done with 
Performa V3 96-well Short Plate and QuickStep2 SOPE Resin (EdgeBio). 
Amplicons were sequenced on an Illumina HiSeq2000 (Illumina) as 101-base 
pair paired-end reads and one 7-base pair index read. 
 
Table 6. Primer sequences for amplicon sequencing 
Target Sequence (5’-3’) 
PDCD10-F AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTT CCGATCTAAACAACTAGGCATAAACCAACA 
PDCD10-R CAAGCAGAAGACGGCATACGAGAT[AAGCTA]GTGACTGGAGTTCAGACGT GTGCTCTTCCGATCTCAACAGGGATATAGCTAGTGCAA 
BRWD3-F AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTT CCGATCTTTTTCAAGTCTCCGCCTGAT 
BRWD3-R CAAGCAGAAGACGGCATACGAGAT[TTGACT]GTGACTGGAGTTCAGACGT GTGCTCTTCCGATCTTAGATTTTGCCAGCCCTTTT 
CREM-F AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCTT CCGATCTTGCTACCATGGCAGTACCAA 
CREM-R CAAGCAGAAGACGGCATACGAGAT[TACAAG]GTGACTGGAGTTCAGACGT GTGCTCTTCCGATCTGGAACAATTTAATGCCAAAACC 
H2AFZ-F AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCT TCCGATCTGGAATCCAGGCATCCTTTAG 
H2AFZ-R CAAGCAGAAGACGGCATACGAGAT[TCAAGT]GTGACTGGAGTTCAGACGT GTGCTCTTCCGATCTCACTTTCTTGGTTTCAAATACTGTG 
PDE6C-F AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCT TCCGATCTGAAAAATCCTGAATTGTATGAACC 
PDE6C-R CAAGCAGAAGACGGCATACGAGAT[GATCTG]GTGACTGGAGTTCAGACGT GTGCTCTTCCGATCTCGTACCTCATCCTGCAACAG 
SDR42E1-F AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCT TCCGATCTCCTAGCTCTTTCTTGGCTTTCTC 
SDR42E1-R CAAGCAGAAGACGGCATACGAGAT[CTGATC]GTGACTGGAGTTCAGACGT GTGCTCTTCCGATCTGACCTTGGTCTACTGCTTTGC 
TP63-F AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCT TCCGATCTGTGAGGGGCCGTGAGACT 
TP63-R CAAGCAGAAGACGGCATACGAGAT[GGAACT]GTGACTGGAGTTCAGACG TGTGCTCTTCCGATCTGCCTCCTAAAATGACACGTTG 
WT1_ex6-F AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCT TCCGATCTCCTGGGTAAGCACACATGAA 
WT1_ex6-R CAAGCAGAAGACGGCATACGAGAT[ATTGGC]GTGACTGGAGTTCAGACG TGTGCTCTTCCGATCTGCTTAAAGCCTCCCTTCCTC 
WT1_ex8-F AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGACGCTCT TCCGATCTTTACCTGTATGAGTCCTGGTGTG 
WT1_ex8-R CAAGCAGAAGACGGCATACGAGAT[GTAGCC]GTGACTGGAGTTCAGACG TGTGCTCTTCCGATCTCCTTGTGGGCCTCACTGT 
Target specific sequences are underlined and index sequences are in brackets. 
 
10.4 Quantification of BCR-ABL1(T315I) transcript levels 
 
Real-time quantitative PCR was used to determine BCR-ABL1(T315I) 
transcript levels in bone marrow of CML patients. The PCR reaction included 
bone marrow cDNA, specific forward primer, a reverse primer and a 
fluorescent TaqMan probe. The initial bone marrow cDNA sample confirmed 
to be T315I positive with Sanger sequencing was used as quantification 
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standard for follow-up samples. A standard curve was generated by diluting 
the cDNA from the T315I positive sample with negative control cDNA in a log-
linear fashion to quantify T315I transcript levels before and after two weeks 
axitinib treatment. The GUS gene was used for data normalization in terms of 
RNA quality and cDNA synthesis. The quantification standard was measured 
in 4 independent runs in duplicate to estimate the between-run variation. The 
samples of interest (before and after axitinib treatment) were measured in 
three replicate analyses.  
 
10.5 RNA sequencing 
 
Gene expression patterns and fusion genes were identified with RNA 
sequencing. First, 2.5-5 µg of total RNA isolated from primary leukemic cells 
was treated with the Ribo-ZeroTM rRNA Removal Kit (Epicentre) to remove 
ribosomal-DNA and RNA samples were further purified with the RNeasy 
Clean-up Kit (Quigen). Following sample clean up, double stranded cDNA 
was generated with the SuperScript™ Double-Stranded cDNA Synthesis Kit 
(Life Technologies). The first-strand synthesis reaction was primed with 
random hexamers (New England BioLabs). The RNA sequencing library was 
created with Nextera Technology (Epicentre), size-selected, and purified with 
QIAquick gel extraction Kit (Quigen). Fifty ng of cDNA was tagmented with 
High Molecular Weight buffer and purified with SPRI beads (Agencourt 
AMPure XP, Beckman Coulter). Transcriptomes were sequenced on an 
Illumina HiSeq2000 instrument with 100-base pairs read length. Paired-end 
and index sequencing were performed with Nextera and index read primers, 
respectively. RNA sequencing data was bioinformatically processed as 
previously described254. 
 
10.6 Fusion gene validation and analysis 
 
In study I, fusion genes detected with RNA sequencing were further validated 
by capillary sequencing of cDNA. Primers were designed to amplify across 
fusion junctions using exon-exon fusion data from transcriptome sequencing, 
the NCBI nucleotide database and Primer Blast (Table 7). The amplification 
reaction contained double stranded cDNA, fusion gene specific primers, and 
Phusion or DyNazyme II DNA polymerase (Finnzymes). The resulting PCR 
products were size-separated on agarose gel and the band of interest purified 
with the NucleoSpin Gel and PCR Clean-up KIT (Macherey-Nagel). Gel-
extracted cleaned up fragments were then directly sequenced or cloned into 
the pCRII-TOPO vector (Life Tecnologies) and the ensuing plasmid 
sequenced with M13 primers. The breakpoints of the fusion genes detected in 
patients 600 and 784 were uncovered with RNA and whole genome 
sequencing.  
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Table 7. NUP98-NSD1, MLL-ELL, ETV6-NTRK3, and STRN-ALK primer sequences 
Primer use Target Sequence 
Fusion gene 
validation 
cNUP98-NSD1-F AGCCTTTGGGGCCCCTGGATTTA 
cNUP98-NSD1-R CCAAAAGCCACTTGCTTGGCTTCC 
cMLL-ELL-F AAGTGGCTCCCCGCCCAAGT 
cMLL-ELL-R AGGAGAACGTCCGCGCCTCT 
cETV6-NTRK3-F CTCCCCGCCTGAAGAGCACG 
cETV6-NTRK3-R GGCATCCAGTGACGAGGGCG 
cSTRN-ALK-F CGGGACAGAATTGAATCAGGGA 
qPCR analysis of 
fusion genes 
gELL-MLL-F CAGGCAGCGCTCACTCGGAAA 
gELL-MLL-R CCTGCTTATTGACCGGAGGTGGT 
gETV6-NTRK3-F TGGTCTGGTTCACGTTTCACTG 
gETV6-NTRK3-R GTAAATCTTCTGCAAAAGGCAGCA 
gSTRN-ALK-F GCTCCTATTATCCTGTCCCTTTGA 
gSTRN-ALK-R TGGCACCATTTAGTGTCATTTAGA 
 
11. Protein analysis 
 
Leukemic patient cells were lysed with RIPA (study I) or SDT buffer (4% SDS, 
0.1 M DTT and 0.1 M Tris; study II).  
 
11.1 Phosphoproteomic arrays 
 
In study I phosphoproteomic profiling of AML patient samples was done with 
Proteome Profiler antibody arrays (R&D Systems) according to 
manufacturer’s instructions. About 300 µg of protein per sample was put on 
the arrays and the signal was visualized with fluorescently labeled streptavidin 
(IRDye 800 CW streptavidin; LI-COR) on an Odyssey imaging system. 
 
11.2 Immunoblotting 
 
In study II, immunoblotting analysis of CRKL phosphorylation status in 
response to axitinib treatment of patient cells derived from a CML patient 
carrying the T315I mutation was performed. Briefly, mononuclear cells 
isolated from a CML patient in lymphatic blast crisis were grown overnight in 
complete medium with 0.1% DMSO or increasing concentrations of axitinib (1-
1,000 nM; 10-fold dilutions). The cells were then centrifuged, washed and 
lysed in SDT buffer (5 x 106 cells/condition). Protein lysates were subjected to 
SDS PAGE and subsequently transferred to a PVDF membrane (Immobilon). 
Prior to primary antibody incubation, the membranes were blocked with 5% 
bovine serum albumin. The following antibodies were used in the western blot 
analysis: rabbit anti-phospho CRKL (Cell Signaling Technologies; 3181) 
1:1,000, mouse anti-alpha tubulin (Sigma Aldrich; T9026) 1:1,000, anti-mouse 
IRDye 680 and anti-rabbit IRDye 800 CW (LI-COR) 1:15,000. Protein bands 
were visualized with the LI-COR Odyssey.  
 
11.3 Enzyme-linked immunosorbent assay (ELISA) 
 
The effect of axitinib treatment on BCR-ABL1 autophosphorylation was 
examined in engineered Ba/F3 cells as previously explained with an ABL1 
phosho-Tyr ELISA. Transformed Ba/F3 cells were seeded in a 96-well plate in 
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assay medium (RPMI-1640 with 0.1% FBS, 0.05% BSA w/v, and 1% 
penicillin/streptomycin) at a concentration of 40,000 cells/well and incubated 
for 2h at 37°C. Axitinib, ponatinib and imatinib were prepared as described in 
9.5. Wells containing 100% DMSO were used as controls. Similarly as in the 
cell proliferation assay 25 µl of compound solution from the 5X source plate 
was transferred to each cell containing well following which the assay plate 
was incubated for additional 2 h at 37°C. The plate was then centrifuged and 
80 µl supernatant was removed from each well. Cells were lysed with Cell 
Signaling Technologies lysis buffer (9803; 100 µl/well) containing 1% SDS, 
protease (Sigma P8340) and phosphatase (Sigma P0044 and P5726) 
inhibitors. The assay plate was then put on a shaker for 10 minutes at 4°C. 
Subsequently, 100 µl of lysate per well was transferred to a goat anti-rabbit 
96-well coated ELISA plate (Pierce 15135) previously incubated with rabbit 
anti-ABL1 antibody (Cell Signaling Technologies 2862). The ELISA plate was 
left to stand at room temperature for 1 h and then washed 4 times with ELISA 
wash buffer (Cell Signaling Technologies; from kit 7903). The secondary 
antibody used was mouse monoclonal (IgG2b) anti-phospho-Tyr antibody 
(Santa Cruz Biotechnology SC508 HRP; 1:5,000). The signal detection was 
done with TMB substrate (Santa Cruz Biotechnology; SC286967) and 
absorbance was measured at 655 nm during color development or at 450 nm 
after reaction stoppage with 0.16 M sulphuric acid stop solution.  
 
11.4 Biochemical kinase assays 
 
In study II, to evaluate whether axitinib inhibits the kinase activity of ABL1 and 
ABL1(T315I) a microfluidic mobility shift assay was performed. The reaction 
volume was 50 µl and consisted of 1 nM GST-tagged intracellular kinase 
domain of human recombinant ABL1 or ABL1(T315I), 3 µM phosphoacceptor 
peptide (5’FAM-EAIYAAPFAKKK-OH; Caliper Life Sciences), axitinib (11-
dose 3-fold serial dilutions) or DMSO only, 1 mM DTT, 0.002% Tween-20 and 
25 mM HEPES (pH 7.1) containing 5mM MgCl2. The assay was started by 
adding ATP (5 µM final concentration) and reactions were incubated for 20 
minutes and then for additional 90 minutes at room temperature. The 
reactions were terminated with addition of EDTA (pH 8). The extent of 
electrophoretic separation of the fluorescently labeled peptide substrate and 
phosphorylated product was detected with the LabChip EZ Reader II (Caliper 
Life Sciences). Inhibitory constants (Ki) were generated with the Morrison 
equation255 for tight-binding competitive inhibition utilizing the non-linear 
regression method, best fit enzyme concentration value and experimentally 
obtained ATP Km (~ 4 µM). 
 
11.5 Recombinant ABL1 production 
 
A construct containing residues 229-515 of human ABL1a (NM_005157.4) 
previously subcloned in an insect cell expression vector was acquired from 
GenScript. The T315I mutation was introduced in this construct with site-
directed mutagenesis. Recombinant baculoviruses, produced with the Bac-to-
Bac method (Invitrogen), were exploited to infect Sf21 insect cells at 27°C. In 
addition, co-infection of ABL1 viruses with baculoviruses expressing human 
YopH tyrosine phosphates at moi = 0.01 was performed to obtain non-
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phosphorylated protein variants. Infected insect cells were isolated after 72 h 
and stored at -80°C before purification. Cell pellets were then lysed with lysis 
buffer and mixed at 4°C for 1 h. The cell lysate was then centrifuged at 5,000 
x g for 1 h after which the supernatant was incubated for 3 h at 4°C with 
ProBond resin (Invitrogen). The ProBond resin bound ABL1 was washed, 
eluted on an Econo column (Bio-Rad), and treated with TEV protease during 
overnight dialysis against wash buffer. The material obtained from the dialysis 
step was put on a fresh column of ProBond resin, which was beforehand 
equilibrated with post-dialysis buffer, allowing for collection of the flow-through 
that contained the detagged ABL1(T315I). The flow-through was then 
dialyzed against delivery buffer. The same procedure was applied for the 
isolation of the kinase domain of ABL1, except that MgCl2 and ADP-NaOH 
were excluded from all buffers. The extracted proteins were snap-frozen in 
liquid nitrogen and stored at -80°C. Protein concentrations were measured 
with Coomassie Plus Protein reagent (Pierce). Buffers used for recombinant 
protein productions are depicted in Table 8.  
 
Table 8. Buffers used for the extraction of recombinant kinase domains of ABL1 and 
ABL1(T315I) 
Buffer Contents 
Lysis buffer 
   50 mM Tris-HCl pH 8 
 200 mM NaCL 
   10 mM MgCl2 
     5 mM ADP-NaOH pH 7.5 
0.25 mM TCEP 
      2 µM leupeptin 
      1 tablet EDTA free protease inhibitor 
Wash buffer 
   50 mM Tris-HCL pH 8 
 400 mM NaCl 
   20 mM imidazole-HCL pH 8 
   10 mM MgCl2 
  2.5 mM ADP-NaOH pH 7.5 
0.25 mM TCEP 
     1 µl leupeptin 
Elution buffer 
   50 mM Tris-HCL pH 8 
 400 mM NaCl 
 250 mM imidazole-HCL pH 8 
   10 mM MgCl2 
  2.5 mM ADP-NaOH pH 7.5 
0.25 mM TCEP 
     1 µl leupeptin 
Delivery buffer 
    25 mM HEPES-NaOH pH7.2 
 250 mM NaCl  
     5 mM MgCl2 
  2.5 mM ADP-NaOH pH 7.5 
20% (v/v) glycerol 
 0.25 mM TCEP      
 
11.6 X-ray crystallography  
 
Once thawed, ABL1 and ABL1(T315I) proteins were diluted with cold 25 mM 
Tris-HCl (pH 8), 150 mM NaCl, and 5 mM DTT to a concentration of 10 µM 
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(~0.3 mg/ml). Then equal parts of 20 µM axitinib (diluted in the same buffer) 
were added to the protein solution and the mixture was incubated on ice for 1 
h. Millipore centrifugal concentrator was used to concentrate the protein-
axitinib solution to ~20 mg/ml. A Mosquito liquid handling device was used to 
generate crystals in SBS format MRC2 crystallization plates via sitting drop 
vapor diffusion. A mixture of 196 nl protein-axitinib solution (17 mg/ml) and 
211 nl reservoir solution (15% w/v PEG 3350, 10 mM MgCl2, 5 mM NiCl2, 5% 
v/v glycerol, and 100 mM HEPES) at 13°C led to the formation of 
ABL1(T315I) crystals. On the other hand, ABL1 crystals were obtained from a 
mixture of 150 nl protein-axitinib solution (18 mg/ml) and 190 nl reservoir 
solution (0.1 M NH4Cl, 20% w/v PEG 3350 and 5% v/v ethylene glycol). The 
crystal drops were first cryo-protected with 4 µl reservoir solution (20% 
glycerol for ABL1(T315I) and 20% ethylene glycol for ABL1) and then 
harvested straight from the crystallization drop and snap-froze in liquid 
nitrogen. The Advanced Photon Source synchrotron (Argonne National 
Laboratories) was used to collect the X-ray data sets at beamline 17-ID, 
wavelength 1.00 Å, and temperature 100 K. For the axitinib:ABL1(T315I) 
complex the Rmerge was 0.055 for data ranging between 65.58 and 2.40 Å, 
whereas for the axitinib:ABL1 complex Rmerge was 0.057 for data in the range 
of 111.81-2-20 Å. Solving the structures involved molecular replacement in 
PHASER256 taking the refined ABL1(T315I) atomic coordinates (axitinib:ABL1) 
or ABL1 structure (wwPDB ID 3IK3; axitinib:ABL1(T315I)) as a starting point, 
repetitious model building and refinement with Coot257 and REFMAC5258, and 
final refinement and validation with the PHENIX system259. For both crystal 
structures, Ramachandran plots showed that majority of the residues are in 
favored regions (97.9% (ABL1(T315I) and 97.1% (ABL1)). The structural data 
has been deposited in Protein Data Bank under accession numbers 4TWP 
(axitinib:ABL1(T315I)) and 4WA9 (axitinib:ABL1).  
 
12. Statistics 
 
Statistical analysis was performed with GraphPad Prism software (studies I 
and II) and R interface (SA I). Drug response profile correlations were 
evaluated with Pearson or Spearman correlation test, whereas two-tailed 
Student t test was used to determine correlation between mutational profiles 
and drug sensitivity. Skewness of drug sensitivity distribution was assessed 
with one-sided D’Agostino test in the R-package ‘moments’ v. 0.13. Difference 
in sensitivity between BRAF(V600E) or RAS mutated and wild-type cells to 
BRAF and MEK inhibitors, respectively, was detected with Wilcoxon rank-sum 
test. ROC curve analysis was applied to estimate the predictive accuracy of 
the different drug sensitivity scoring metrics in differentiating active drugs from 
inactive ones using R-packages ‘verification’ and ‘pROC’. Adjusted Rand, 
Jaccard and Fowlkes-Mallows indices were used to measure similarities in 
drug clustering in terms of mode of action between DSS, Activity Areal and 
pIC50. The difference in T315I transcript levels in bone marrow before and 
after axitinib treatment was inferred with un-paired two-tailed t test with 
Welch’s correction. A P-value ≤ 0.05 was considered statistically significant. 
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RESULTS 
 
13. Development of an Individualized Systems Medicine platform 
 
To identify and optimize novel treatment strategies for leukemia patients an 
Individualized Systems Medicine (ISM) platform was developed (Figure 12). 
The ISM platform encompasses comprehensive functional and molecular 
profiling of leukemia patient cells with an oncology drug collection and 
genomic and transcriptomic sequencing, respectively. This approach 
facilitates evaluation of ex vivo drug sensitivity of cancer cells and uncovers 
underlying disease mechanisms and molecular drivers. In addition, it holds 
promise for rapid translation of results and identification of drugs that can be 
repurposed for treatment of leukemia patients. Furthermore, this strategy 
makes it possible to monitor disease progression, therapy response and 
clonal evolution by studying consecutive samples from the same patient 
before and after relapse. The functional and molecular information is also 
integrated with clinical features to guide therapy decisions. 
 
 
Figure 12. Integrated individualized systems medicine platform involving ex vivo drug 
sensitivity and resistance testing (DSRT) and deep molecular profiling as means of 
personalized therapy optimization for cancer patients.  
 
13.1 DSRT of leukemia patient cells 
 
To establish an unbiased functional readout for cellular vulnerabilities of 
individual cancer samples, an ex vivo drug sensitivity and resistance testing 
(DSRT) screening platform was developed that covers the approved cancer 
small molecule pharmacopeia and the active substances of emerging 
investigational and experimental cancer drugs. The availability of a large 
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number of drugs that target oncogenic signals and signaling pathways allows 
for an increasingly comprehensive functional profiling of cancer patient cells 
and their dependencies and addictions to cellular signals. This thesis 
describes the analysis of ex vivo drug sensitivity profiles of 28 primarily 
relapsed and refractory AML (study I and SA I), 6 Ph+ (study II), and 7 healthy 
donor bone marrow samples (studies I-II, and SA I). With the established 
DSRT culture conditions, majority of patient and healthy donor control 
samples exhibited relative cell viability above 50% following 72 h incubation 
without drug treatment (Figure 13). The malignant cell count of each sample 
did not correlate with the relative cell viability after 72 h incubation (Figure 12). 
Moreover, drug sensitivity data analysis divulged that the DSRT platform is 
robust and reproducible and that the profiles of healthy bone marrow control 
samples were highly in accordance (Figure 14).  
 
 
Figure 13. Relative ex vivo cell viability in AML patient samples after a 72 h 
incubation period in 384-well plates without drug treatment (left) and correlation with 
blast count (right). 
 
 
Figure 14. DSRT data from sample replicates (left) and from different healthy donor 
control samples (right) exhibit excellent correlation. DSS correlation plot of a patient 
sample screened twice (as two independent experiments) and DSS scatterplots of 
each of the 7 healthy donor samples with mean and standard deviation as error bars.  
 
13.2 DSRT profiles of AML patient samples 
 
Numerous targeted signal transduction inhibitors exhibited little or no effect in 
the controls and in majority of AML patient samples and only a subset of 
patient samples display selective responses to these agents, illustrating that 
the inhibitors are hitting subgroup specific addictions. Moreover, drug 
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sensitivity profiles of AML patient samples were distinctly different from those 
of control samples, suggesting that leukemia specific inhibitory effects are 
detected with the DSRT screening platform (Figure 15A). The differences 
between healthy donor and leukemia patient samples could mostly be 
attributed to targeted drugs (Figure 15A-B), as the overall sensitivity to 
classical chemotherapeutics was largely comparable in patient and control 
samples with the exception of cytarabine (Figure 15A,C). Hence, 
chemotherapy agents have a narrower therapeutic window and their efficacy 
in vivo is more challenging to predict based on ex vivo drug sensitivity data. 
Meaningful leukemia-selective responses were detected to the broad TKIs 
dasatinib (36% of the samples) and sunitinib (36%), MEK inhibitors (trametinib 
36%), rapalogs (temsirolimus 32%), and other TKIs such as foretinib (32%), 
ponatinib (25%), ruxolitinib (25%), dactolisib (25%), MK-2206 (21%), 
sorafenib (21%), and quizartinib (18%; Figure 15D-E). 
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Figure 15. Targeted agents display leukemia-selective responses in AML. A. 
Comparative analysis of ex vivo drug responses (DSS) to chemotherapeutics (left) 
and targeted agents (right) in 28 AML and 7 control samples. Error bars signify mean 
with standard deviation. B-C. Distribution of sensitivity to sunitinib (broad TKI) and 
daunorubicin (topoisomerase II inhibitor) in the study cohort expressed as standard 
deviations from the mean control DSS response (Z-score). D-E. The percentage of 
patient samples responding to select targeted agents as assessed by sDSS 
represented with a bar graph and a heatmap of relationships between different 
selective drug responses. 
 
In order to measure differential drug effect as compared to healthy donor 
control samples, unsupervised hierarchical complete linkage clustering with 
spearman correlation distance measure of sDSS was employed. This 
approach facilitated stratification of patients based on drug efficacy patterns 
across all drugs screened as well as taxonomy of drugs in terms of responses 
among all patients in this particular disease setting. The cluster analysis 
showed that each AML patient sample has an overall distinct drug sensitivity 
profile. However, based on correlative drug responses the AML patient 
samples could be functionally classified in 5 robust subgroups. All of the 
patient sample subgroups could be characterized by either sensitivity or not 
sensitivity to certain drug classes (Figure 16). Majority of patient samples 
exhibited selective responses to navitoclax (BCL-2/BCL-XL inhibitor), HSP90 
and histone deacetylase (HDAC) inhibitors. Subgroup I was largely insensitive 
to the tested compound panel with the exception of navitoclax. Subgroup II 
was defined by selective sensitivity to immunomodulators (dexamethasone 
and prednisolone), MEK and Janus-activated kinase (JAK) inhibitors. Contrary 
to subgroups I and II, subgroups III, IV and V displayed increased sensitivity 
to a wide range of TKIs, suggesting that their AML was either driven or 
addicted to RTK signaling pathways. In addition to TKIs, subgroup III showed 
sensitivity to HSP90, HDAC and PI3K/mTOR inhibitors similarly to samples 
falling in subgroups IV and V but with lower intensity. Subgroup IV was also 
defined by strong sensitivity to MEK and PI3K/mTOR inhibitors, whereas 
subgroup V by potent selective responses to RTK inhibitors (targeting ABL1, 
VEGFR, PDGFR, FLT3, and KIT), PI3K/mTOR and topoisomerase II 
inhibitors. Strikingly, almost 70% of the AML patient samples exhibited 
moderate to strong sensitivity to TKIs in line with previous studies235. 
 
Clustering of compounds across AML and control samples revealed that 
inhibitors with related mode of actions in majority of cases highly correlated 
(clustered together) such as immunomodulators, MEK inhibitors, HSP90 
inhibitors, HDAC inhibitors, PI3K/AKT/mTOR inhibitors, ABL1, KIT and 
VEGFR targeting TKIs, and topoisomerase II inhibitors. These findings are not 
only supporting the notion that anti-leukemia specific drug responses are 
detected with the DSRT platform, but also that the DSRT analysis is 
consistent and reproducible and can derive biologically and clinically relevant 
data. However, unexpected clusters were also observed with quizartinib’s 
responses correlating with those of topoisomerase II inhibitors, whereas 
ponatinib’s clustered with cytarabine, HSP90 and HDAC inhibitors. These 
revelations suggest that the activity of these agents in AML may be 
functionally linked and could aid in elucidating critical molecular mechanisms 
of action in this disease setting. Moreover, AML specific drug clustering 
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results can be utilized to design subtype-specific drug combinations strategies 
to be clinically explored, which would not be otherwise identified without 
unbiased DSRT profiles. For example, responses of MEK inhibitors highly 
correlate with either JAK or PI3K/mTOR inhibitors in subgroups II and IV, 
respectively. In addition, FLT3 inhibition is associated with dasatinib (does not 
target FLT3) sensitivity in subgroup V, especially in M5 categorized patients 
(Figure 17). This indicates that these compounds may inhibit the same or 
linked signaling pathways and poses the question whether a combined 
treatment will be synergistic in that particular patient population. 
 
13.3 Associations between functional and molecular profiles 
 
To determine whether there are links between genomic and drug sensitivity 
data, the distribution of mutations in most frequently altered genes in AML, as 
per TCGA76 data, with DSRT-based sample taxonomy was assessed. An 
enrichment of FLT3-ITD mutations in samples falling in subgroup V was 
observed, which was the most tyrosine kinase-addicted group. Hence, FLT3-
ITD mutational status can serve as an indicator whether a patient would 
respond to tyrosine kinase inhibition. Furthermore, subgroup V was defined by 
sensitivity to a number of FLT3 inhibitors such as foretinib, quizartinib and 
sunitinib, indicating that sensitivity to FLT3 inhibitors link to activating FLT3 
mutations. However, 4 out of 5 patient samples in this subgroup exhibited 
strong sensitivity to dasatinib that does not have FLT3 inhibitory activity, 
implying that AMLs with FLT3 mutations are also reliant on additional tyrosine 
kinase signals. Overall, dasatinib sensitivity was highest in patient samples 
harboring FLT3 mutations (P = 0.0034) and AML M5-diagnosed samples (P = 
0.0004) (Figure 17). In particular, FLT3, ATP-competitive mTOR, 
topoisomerase II inhibitors and navitoclax were selective in AML-M1 samples, 
whereas navitoclax, mTOR inhibitors and the IGF1R/InsR inhibitor linsitinib 
exhibited selective responses in AML-M2 patient samples. Besides selective 
responses to dasatinib, AML M5 samples displayed enhanced sensitivity to 
tivozanib, a number of broad TKI targeting FLT3, HSP90 inhibitors, mTOR 
inhibitors and the MEK inhibitor refametinib (Figure 17). Therefore, the FAB 
classification of AML cases may serve as a guideline for some types of 
personalized therapies.  
 
Activating mutations in RAS and MLL fusions were associated with MEK 
inhibitor sensitivity, whereas TP53 mutations were enriched in subgroups I 
and II and linked to adverse karyotype. While all RAS mutated samples 
exhibited MEK inhibitor sensitivity, not all MEK inhibitor sensitive samples 
harbored RAS mutations. This indicates that there are additional factors that 
confer MEK inhibitor sensitivity in AML. Associations between mutations 
and/or fusions and epigenetic modulation in subgroups III and IV were also 
observed. Hence, some links from phenotype to genotype were detected, but 
for most drug responses detected no clear link to genotype could be 
elucidated.  
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Figure 16. Ex vivo anti-cancer sensitivity testing identifies promising therapies for 
subgroups of AML patients. A heatmap of drug sensitivity profiles (expressed as 
sDSS) of 28 AML and 7 control samples separates AML patient samples in 5 
functional taxonomic groups. Selective drug responses are depicted in red, whereas 
drugs that exhibit lower efficacy in AML patient samples than control samples are in 
blue. The unsupervised clustering was performed with the complete linkage method 
with Euclidian (samples) and Spearman (drugs) distance measures. Significant 
mutations and gene fusions are also depicted to correlate drug sensitivity and 
mutation data. 
 
 
Figure 17. Sensitivity to dasatinib in AML patient and healthy donor control samples 
where the AML samples are stratified based on FLT3 mutational status or FAB 
subtype. Correlations between drug sensitivity profiles of AML M1, M2 or M5 and 
healthy bone marrow controls further highlight compounds (in red) with cancer-
specific activity in the AML subgroups.  
 
13.4 A subset of AML patient samples is highly sensitive to MEK 
inhibitors 
 
MEK inhibitors have been explored in clinical trials for AML in the past without 
significant success, suggesting that either MEK is not a relevant target in the 
AML setting or more likely that the appropriate subgroup of patients has not 
been identified. The four MEK inhibitors included in the oncology collection in 
study I, selumetinib, trametinib, refametinib and pimasertib, exhibited highly 
consistent response pattern across the AML patient samples and no or very 
minor effect in the healthy donor control samples (Figure 18). The overall drug 
response pattern to MEK inhibitors varied in different samples, with 12 
samples displaying no, 7 partial and 9 significant sensitivity. Together this 
data indicates that the DSRT approach can stratify patient samples in terms of 
MEK inhibitor sensitivity and identify candidate patients for tailored MEK 
inhibitor therapy. No clear link between MEK signaling and a specific RTK 
was observed, as no RTK inhibitor exhibited analogous sensitivity pattern with 
Dasatinib sensitivity
Healthy
donor
controls
FLT3
mutated
samples
Non-FLT3
mutated
samples
0
5
10
15
20
D
SS
**
*
0 5 10 15 20 25
0
5
10
15
20
25
Dasatinib
Q
ui
za
rti
ni
b
AML M5AML M1
Dasatinib
Primary samples
Controls M1 M2 M5 Other
D
S
S
0
5
10
15
20
25
**
* **
***
0 5 10 15 20 25 30 35
0
5
10
15
20
25
30
35
 Controls (Average DSS)
AM
L 
M
1 
(A
ve
ra
ge
 D
SS
)
Idarubicin
Navitoclax
Foretinib
Tipifarnib
Ponatinib
PF-04691502AZD8055
Luminespib
Lestaurtinib
Teniposide
Dactinomycin
Sunitinib
Quizartinib
Gandotinib
0 5 10 15 20 25 30
0
5
10
15
20
25
30
 Controls (Average DSS)
AM
L 
M
2 
(A
ve
ra
ge
 D
SS
)
Navitoclax
BIIB021
PF-04691502
AZD8055
Linsitinib
0 5 10 15 20 25 30
0
5
10
15
20
25
30
 Controls (Average DSS)
AM
L 
M
5 
(A
ve
ra
ge
 D
SS
)
Plicamycin
Tanespimycin
BIIB021
Ponatinib
PF-04691502
Tivozanib
AZD7762
AZD8055
Refametinib Luminespib
Lestaurtinib
Dasatinib
Temsirolimus
Sunitinib
Midostaurin
UCN-01
	   57	  
the MEK inhibitors. This suggests that the mechanism underlying MEK 
addiction may be dependent on other factors such as DUSP6 (phosphatase 
specifically inactivating pERK2) expression, which has been shown to be an 
independent predictor of MEK inhibitor sensitivity260. 
 
 
Figure 18. MEK inhibition is a potentially promising therapeutic strategy in a subset of 
AML patients. The 9 samples underlined in the top panel are separated by the 
dashed line in the bottom left panel. Dose response curves for trametinib treatment in 
3 selective (red), 3 insensitive (blue) and average control (n = 7; black) samples 
show a highly cancer cell–selective response pattern with a low level of activity in 
control samples, suggesting a potential for wide therapeutic window. 
 
13.5 mTOR and upstream signals as molecular targets in AML 
 
Ten out of the 28 AML patient samples were sensitive to rapamycin and its 
analogs (temsirolimus and everolimus) (Figure 19), a class of indirect mTOR 
complex 1 inhibitors that are approved for oncology and non-oncology 
indications. Drug sensitivities to the 3 rapalogs were highly concordant among 
the samples with everolimus and sirolimus clustering together in the full DSRT 
dataset (Figure 16). Of the three, temsirolimus consistently reduced viability of 
AML cells with highest intensity. While everolimus and sirolimus clustered 
relatively close to ATP-competitive PI3K/AKT/mTOR pathway inhibitors, they 
grouped closest to methotrexate and floxuridine and temsirolimus with 
lestaurtinib, ponatinib and cytarabine. This suggests that rapalogs and the 
ATP-competitive PI3K/AKT/mTOR inhibitors, at least in part, affected different 
cellular mechanisms. One striking difference between the two compound 
types was that while rapalogs exhibited extremely wide therapeutic windows 
with effects on sensitive patient samples often in the sub-nanomolar range 
and no toxicity in the control cells until low micro-molar concentrations, all the 
ATP-competitive PI3K/AKT/mTOR pathway inhibitors had considerable 
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effects on the control cells already at concentrations relatively close to the 
cancer-specific effective concentrations. One patient sample (600_2) out of 7 
that were significantly sensitive to rapalogs did not respond selectively to an 
ATP-competitive mTOR inhibitor (AZD8055, targeting mTORC1 and 
mTORC2), a pan PI3K inhibitor (pictilisib) or an AKT inhibitor (MK-2206). 
Similarly, several (1280 and 1497) of the samples that selectively responded 
to PI3K/AKT/mTOR inhibitors did not respond strongly to rapalogs (Figure 
19). Therefore, while rapalogs emerge as promising agents in a subset of 
AML samples that could be identified through DSRT, the mechanism of 
sensitivity to rapalogs appears to be more complex that just through an 
activation of the PI3K/AKT/mTOR pathway. 
 
 
Figure 19. Rapalogs induce selective ex-vivo responses in a subset of AML patient 
samples and their activity profile is distinct from other PI3K/AKT/mTOR inhibitors. 
Distribution of temsirolimus sensitivity in the AML and control samples highlighted 7 
samples with significant responses (separated with a dashed line). Temsirolimus 
dose response curves for 3 responders, 2 non-responders and the average of 
responses in controls samples are shown shown in red, blue and black, respectively. 
Heatmap depicting the inter-relationships of samples responding to temsirolimus, 
ATP-competitive mTOR inhibitors (AZD8055, dactolisib, and OSI-027), AKT inhibitor 
(MK-2206), and PI3K inhibitors (pictilisib and idelalisib. Responses are depicted as 
strong (red), intermediate (pink) or low (pale pink).  
 
13.6 Drug sensitivity profiles of Ph+ leukemia patient samples 
 
In addition to AML, the DSRT platform was also applied to 3 CML and 3 Ph+ 
ALL patient samples (study II). Four samples from the Ph+ patient cohort 
harbored the BCR-ABL1(T315I) mutation (155, 542, 1278 and 1408), one had 
no detectable point mutations (410) and one of the CML patient samples 
carried BCR-ABL1(E255K) and BCR-ABL1(V299L) mutations (651). Patient 
samples with T315I mutations were not sensitive to imatinib, dasatinib and 
nilotinib, but exhibited sensitivity to ponatinib as expected (Figure 20). Varied 
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degree of sensitivity to a number of inhibitors targeting main BCR-ABL1 
downstream effector signals were observed such as BCL-2/BCL-XL, MEK, 
JAK, and PI3K/AKT/mTOR. Furthermore, immunomodulators and inhibitors of 
KIT, PDGFR and VEGFR showed activity in Ph+ patient cells (Figure 20). In 
addition to ponatinib, patient samples carrying the T315I mutation displayed 
potent selective responses to the aurora kinase inhibitor danusertib, a probe 
with known efficacy against T315I-positive cells261, PI3K/mTOR inhibitors and 
unexpectedly to the VEGFR2 inhibitor axitinib. The median IC50 values 
detected for axitinib were 20-fold lower in patient cells harboring T315I 
mutations in comparison to T315I-negative Ph+ cells. Interestingly, no other 
VEGFR, PDGFR or KIT targeting TKI showed comparable efficacy in the 
patient samples with T315I mutations, indicating that axitinib is inhibiting a 
different target in these cells. Axitinib, highly-selective for VEGFR262, was 
developed by Pfizer and is currently approved for refractory renal cell 
carcinoma patients as an angiogenesis inhibitor263. Axitinib has not been 
previously explored in the context of biochemical or cellular BCR-ABL1 
inhibition. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Heatmap of selected drug sensitivities and their main targets in CML and 
Ph+ ALL patient samples. BCR-ABL1 mutational status is also shown to correlate 
genotype to phenotype. 
 
Targets 651 410 542 1278 1408 155
Imatinib
Dasatinib
Nilotinib
Ponatinib
Aurora and ABL1 Danusertib
Dexamethasone
Methylprednisolone
Prednisolone
BCL-2/BCL-Xl Navitoclax
Trametinib
Refametinib
Selumetinib
Pimasertib
MEK-162
TAK-733
Ruxolitinib
Gandotinib
Momelotinib
AZD1480
Tofacitinib
Idelalisib
Buparlisib
Pictilisib
GSK2126458
GDC-0980
Dactolisib
PF-04691502
AKT MK-2206
Temsirolimus
Everolimus
Sirolimus
Ridaforolimus
AZD8055
OSI-027
INK128
Axitinib
Masitinib
Sunitinib
Regorafenib
Nintedanib
Foretinib
MGCD-265
Motesanib
Tivozanib
CML CML Ph+ ALL Ph+ ALL CML Ph+ ALL
E255K, V299L
mTOR
KIT, PDGFR, VEGFR
ABL1
Immunomodulators
MEK1/2
JAK
PI3K/mTOR
Rapalogs; MTORC1
T315I
	   60	  
13.7 Drug sensitivity studies in cell lines  
 
To assess the workability of the DSS in more controlled settings, the DSS 
analysis pipeline was applied to drug sensitivity data from the CCLE study. In 
particular, the sensitivity of a MEK inhibitor (selumetinib) in wild-type or RAS 
mutated hematopoietic and lymphoid cell lines was explored (Figure 21). 
Comparison of the DSS with AA metrics (used in the CCLE study) or 
conventional IC50 analysis illustrated that DSS and AA delivered comparable 
power in detecting selective responses of the MEK inhibitor in RAS mutated 
cell lines (P = 0.0003 and P = 0.0032) in comparison to the wild-type 
counterpart, whereas the IC50 metric did not show statistically significant 
difference in MEK inhibitor sensitivity (P = 0.0954). In addition, the DSS was 
capable of further distinguishing the difference in sensitivity between wild-type 
and mutated cell lines, as the DSS scored the drug responses in wild-type 
cells lower than the Activity Area. These data show that drug response 
quantification with DSS surpasses conventional drug sensitivity scoring 
metrics such as IC50 and has similar selectivity to the Activity Area.  
 
 
Figure 21. Distribution of sensitivities to selumetinib in hematopoietic and lymphoid 
cell lines quantified with DSS, Activity Area (AA), and pIC50. Ns-non significant, ***-P 
< 0.0005, **-P < 0.005. 
 
In order to determine whether the observed activity of axitinib in Ph+ patient 
cells with T315I mutations was as a result of specific inhibition of BCR-
ABL1(T315I), murine pro-B Ba/F3 cells transformed to stably express BCR-
ABL1 or BCR-ABL1(T315I) were utilized. In this cell model the ability of 
axitinib to inhibit ABL1 autophosphorylation and BCR-ABL1-dependent cell 
proliferation was evaluated. In line with the effects of ponatinib, axitinib 
potently and selectively diminished autophosphorylation of ABL1(T315I) and 
inhibited the growth of BCR-ABL1(T315I) positive Ba/F3 cells in a dose 
dependent manner (Figure 22). In contrast, the effects of axitinib in 
engineered Ba/F3 cells expressing BCR-ABL1 were 10-fold lower. In a larger 
panel of transformed Ba/F3 cells with clinically important BCR-ABL1 
resistance mutations, axitinib exhibited highly selective efficacy towards cells 
harboring gatekeeper mutations. Thus, axitinib can specifically and efficiently 
target gatekeeper-mutant BCR-ABL1. 
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Figure 22. Axitinib blocks BCR-ABL1(T315I) autophosphorylation and proliferation of 
Ba/F3 cells expressing BCR-ABL1(T315I) in a dose dependent manner as measured 
with phospho ABL1 ELISA and resazurin cell viability assay, respectively. Error bars 
indicate standard deviation of mean of several repeated experiments. 
 
14. Clinical implementation of DSRT data 
 
Several criteria had to be met for DSRT data to be considered translatable, 
namely that distinctive leukemia selective response was detected, the 
translation candidate drug/s were accessible for compassionate or off-label 
use, and for the patient in question no other treatment strategy to be feasible. 
In the studies included in this thesis, DSRT-guided treatment was given to 8 
AML and 1 CML patient. Responses to clinical therapy were evaluated 
according to ELN criteria9 and 3 out of 9 patients achieved a response to 
DSRT-optimized therapy (Table 9). One patient (600; full disease course in 
section below) achieved complete remission with incomplete platelet recovery 
on dasatinib-sunitinib-temsirolimus treatment and two patients (718 and 800) 
achieved morphologic leukemia-free state on sorafenib-clofarabine and 
dasatinib-clofarabine-vinblastine, respectively. 
 
In addition, responses, not meeting ELN response criteria were also detected 
in 4 other AML patients and 1 CML patient. Five days of dasatinib-sunitinib 
treatment led to rapid clearance of peripheral blood blasts in patient 560, but 
treatment had to be terminated due to gastrointestinal toxicity. Patient 252 
(AML with 3 previous relapses) attained 8-week progression free survival on 
dasatinib treatment. In patient 784 the combination of dasatinib, sunitinib and 
temsirolimus caused a reduction in bone marrow blasts (from 70% to 35%), 
but the response was short-lived due to selection of a resistant clone. In the 
course of ruxolitinib-dexamethasone treatment of patient 1145, hematologic 
improvement was observed. One CML patient (1408) in lymphatic blast crisis, 
which had failed both imatinib and dasatinib, achieved a 5-fold reduction in 
BCR-ABL1(T315I) transcript levels in bone marrow following 2 week axitinib 
treatment. Hence, even patients with transient clinical responses had a 
significant impact on the clonal evolution of the tumors and selection of 
mutations potentially contributing to drug resistance. Thus, comprehensive 
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genomic profiling of such patient cases is critical to evaluate the therapy effect 
and decipher mechanisms of drug sensitivity and resistance.  
  
Table 9. Responses to DSRT-directed therapy based on ELN 2009 criteria  
Patient DSRT-guided treatment 
Treatment 
duration 
(days) 
Disease 
state at 
treatment 
start 
Treatment 
response 
Additional 
information 
Time to 
progression 
(weeks) 
252 Dasatinib 59 
Relapsed, 
resistant 
disease 
RD 
Bone marrow 
blasts: 65-40-
75% 
8 
560 Dasatinib- temsirolimus 34 
Relapsed, 
remission RD 
Induction w. 
plerixafor-
MAC 
4 
560 Dasatinib-sunitinib 5 
Relapsed, 
resistant 
disease 
RD Blood blasts 34-0% N/A 
600 
Dasatinib-
sunitinib-
temsirolimus 
44 
Relapsed, 
resistant 
disease 
CRi  6 
718 Sorafenib-clofarabine 63 
Relapsed, 
resistant 
disease 
Morphologic 
leukemia-free 
state 
Hypoplasia Not further follow-up 
784 
Dasatinib-
sunitinib-
temsirolimus 
13 Resistant disease RD 
Bone marrow 
blasts: 70-35-
85% 
Not 
evaluable 
800 
Dasatinib-
clofarabine-
vinblastine 
6 Resistant disease 
Morphologic 
leukemia-free 
state 
Hypoplasia 
Hypoplasia, 
no disease 
progression 
1145 Ruxolitinib-dexamethasone 48 
Relapsed, 
resistant 
disease 
RD Hematologic improvement 6 
1408 Axitinib 14 Resistant disease N/E 
5-fold 
reduction of 
BCR-
ABL1(T315I) 
transcript 
levels 
Allogeneic 
HSCT 
currently in 
CR 
CRi-complete remission with incomplete platelet recovery; HSCT-hematopoietic stem 
cell transplant; RD-refractory disease; MAC-mitoxantrone, cytarabine, etoposide; 
morphologic leukemia-free state-bone marrow blasts < 5%, absence of blasts with 
Auer rods, absence of extramedullary disease, no hematologic recovery required; 
N/A-not available; N/E-not evaluable. 
 
14.1 DSRT accurately recapitulates drug resistance in vivo 
 
Patient 600 was a 54-year old male diagnosed with AML FAB M5 with normal 
karyotype and presence of an FLT3-ITD mutation. The patient failed 3 
consecutive induction therapies and had a relapsed and refractory disease. 
Mononuclear cells isolated from the bone marrow of this patient were 
subjected to DSRT and in-depth molecular profiling to possibly identify 
molecular drivers and individualized therapy. The DSRT data showed strong 
selective responses for a number of tyrosine kinase inhibitors, including 
dasatinib and sunitinib, HSP90 inhibitors and rapalogs (Figure 23). Based on 
these results as well as availability of drugs the patient was treated with a 
combination of dasatinib, sunitinib and temsirolimus in an off-label 
compassionate use setting. This treatment strategy resulted in very quick 
reduction of bone marrow blasts and striking improvement of the clinical 
condition of the patient. Concurrently, a normalization of the bone marrow 
hematopoiesis ensued and the patient achieved complete remission with 
incomplete platelet recovery (Figure 24). The patient was able to leave the 
hospital for the first time in 6 months. However, the duration of therapy 
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response was approximately 30 days after which the patient relapsed. A new 
DSRT analysis of the relapsed cells indicated that there was a significant loss 
of sensitivity to not only the drugs the patient was treated with, but also to 
majority of the compounds in the DSRT panel. Hence, there was a perfect 
correlation between in vivo and ex vivo responses.  
 
 
Figure 23. DSRT data and clinical implementation of DSRT results in a relapsed and 
refractory AML patient. The bar graph depicts the top leukemia selective compounds 
in patient sample 600_2 and the corresponding sensitivities to those agents in the 
relapsed sample 600_3. The correlation of the overall drug sensitivity profiles before 
and after relapse from dasatinib, sunitinib and temsirolimus treatment shows an 
omni-resistant phenotype. Drugs that had the strongest loss of sensitivity are marked 
in blue, intermediate loss in yellow and comparable sensitivity in green.  
 
RNA sequencing data of RNA isolated from the 600_2 sample identified the 
presence of the fusion gene NUP98-NSD1 (Figure. 24) from a cryptic 
chromosomal rearrangement t(5;11)(q35;p15.5). Retrospective and 
prospective analysis showed the fusion transcript was present already at 
diagnosis and persisted following relapse from dasatinib, sunitinib and 
temsirolimus therapy, indicating that this fusion was involved in leukemia 
initiation. This genomic alteration264 is relatively prominent in CN pediatric 
AML265,266, but infrequent in adult AML267. Exome sequencing revealed a 
distinct clonal and subclonal evolution characterized by two different FLT3-
ITD and four different WT1 mutations (Figure. 24). To elucidate a model of 
disease progression, exome sequencing results were integrated with qPCR-
measured alterations of the relative FLT3-ITD levels. The founding clone was 
defined by the fusion NUP98-NSD1 and mutations with stable tumor variant 
frequencies throughout the disease course. In addition, five other clones were 
detected. Clone 1, which was derived from the founding clone, was the 
dominant clone at diagnosis and was composed of mutations specific to the 
diagnostic sample (FLG2 and WDR5) and FLT3-ITD #1. Clone 2 was also 
derived from the founding clone and was defined by H2AFZ, SDR42E1, WT1 
#1 and FLT3-ITD #2 mutations. In contrast, clone 3, 4, and 5 evolved from 
clone 2 by acquiring additional WT1 mutations (#2, #3, and #4 respectively). 
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Figure 24. Clinical follow-up and clonal evolution analysis of the patient 600. The 
clinical graph shows alterations in blast and neutrophil counts in response to DSRT-
guided treatment. The predicted protein structure of the NUP98-NSD1 fusion is also 
depicted and a summary plot of the composition of the distinct clones identified from 
the diagnosis, before and after DSRT-guided treatment samples with exome 
sequencing. Clones 1, 2 and 3 were present at diagnosis, clone 2, 3, 4 and 5 before 
relapse (600_2) and clone 2,3 and expanded clone 4 after relapse (600_3). 
 
Since DSRT data of patient sample 600_2 demonstrated strong sensitivity to 
a number of FLT3 inhibitors (sunitinib, quizartinib, ponatinib, lestaurtinib, 
sorafenib) it is likely that FLT3 was one of the key disease drivers. However, 
dasatinib, sunitinib and temsirolimus treatment most probably led to the 
selection of a resistant clone, which albeit still containing the second FLT3-
ITD conferred resistance to therapy. The drug resistance was accompanied 
with reduced phosphorylation of AKT, CHK2, CREB, ERK1/2, FAK, p38α, and 
STAT1. Genomic information did not fully elucidate the mechanism of drug 
resistance and disease progression as at relapse no novel mutations were 
detected, but rather a redistribution of the frequency of the already existing 
clones. Hence, other factors such as epigenetic modifications might have 
played a role in the development of the resistance phenotype in this patient.  
 
14.2 DSRT and molecular profiling suggests mechanism of drug 
sensitivity and resistance 
 
A 37-year old previously healthy woman presented with dysplastic changes in 
myelo- and thrombopoiesis. The patient was diagnosed with AML that was 
defined by a recurrent translocation t(11;19)(q23;p13.1) resulting in the MLL-
ELL fusion gene. The patient relapsed following 3 rounds of conventional 
therapy. At that time point in the disease course (784_1), a bone marrow 
sample was taken for DSRT and molecular profiling. DSRT data revealed 
marked selective responses to MEK inhibitors, rapalogs, and a number of 
TKIs (e.g. dasatinib; Figure 25). Based on this data the patient was also 
treated with the dasatinib, sunitinib, and temsirolimus combination. This 
treatment regimen caused a rapid reduction of peripheral leukocytosis and 
bone marrow blasts, but the duration of the response was relatively short. The 
blast counts started to rise approximately 7 days following therapy 
commencement. The resistant cells (784_2) were also profiled with DSRT, 
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exome and RNA sequencing. The drug sensitivity profile of the 784_2 sample 
showed that the patient cells were not anymore sensitive to dasatinib and 
rapalogs, but exhibited comparable sensitivity to MEK inhibitors and ATP-
competitive mTOR inhibitors (e.g. dactolisib and AZD8055) as the 784_1 
sample (Figure 25). Strikingly, the resistant cells displayed sensitivity to 
several drugs and drug classes to which they were previously either not 
sensitive or had low level of sensitivity: BMS-754807 (IGF1R/Trk inhibitor), 
crizotinib (ALK inhibitor), tipifarnib (farnesyltransferase inhibitor), several 
topoisomerase II inhibitors and immunomodulators. 
 
  
Figure 25. DSRT data and its clinical implementation in a relapsed and refractory 
AML patient. The bar graph depicts the top leukemia selective compounds in patient 
sample 784_1 and the corresponding sensitivities to those agents in the relapsed 
sample 784_2. The correlation of the overall drug sensitivity profiles before and after 
relapse from dasatinib, sunitinib and temsirolimus treatment is depicted on the right. 
Drugs that had the strongest loss of sensitivity are marked in blue, intermediate loss 
in yellow, retained sensitivity in green, and gain of sensitivity in pink and red.  
 
The DSRT data before and after relapse was integrated with publicly available 
kinase inhibitor target specificity profiles246 to perform a kinaddictome 
analysis, which revealed a significant shift in kinase addiction. In the pre-
resistance sample the cells were deemed dependent on SRC family, PI3K 
and p38 mitogen-activated protein kinases, whereas that dependency was 
lost in the relapsed sample that gained addiction to ALK and Trk family RTKs. 
The loss of response to dasatinib, sunitinib and temsirolimus was 
accompanied with over 1,000-fold enrichment of two fusion transcripts ETV6-
NTRK3 and STRN-ALK (Figure 26). This suggests that preexisting small 
subclones were selected with therapy and led to drug resistance. The fusion 
gene ETV6-NTRK3 encodes for the TEL-TrkC fusion protein with oncogenic 
properties, while the STRN-ALK was out of frame and could not code for a 
functional protein. In addition, the resistance phenotype was characterized 
with increase in the phosphorylation status of p70S6 kinase and CREB 
(Figure 26), implying a hyperactivation of mTORC1 that is a reported 
mechanism of resistance to rapamycin analogs268.  
 
The fusion gene MLL-ELL was detected in all samples from patient 784, 
suggesting it was the leukemia-initiating event. At diagnosis the patient 
harbored two distinct FLT3-ITD mutations, which were lost following induction 
chemotherapy. In addition a WT1 mutation was also detected at diagnosis, 
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which was amplified by loss of heterozygosity (LOH) at the WT1 locus in 
following samples (784_1 and 784_2). In contrast, the frequencies of most 
other mutations observed in this patient remained stable throughout the 
disease progression, suggesting that they were derived from the founding 
clone. The altered sensitivity pattern to the dual IGF1R/TrkC inhibitor BMS-
754807 in samples 784_1 and 784_2, suggests that the TEL-TrkC fusion 
protein became the disease driver in the resistant sample. Moreover, TEL-
TrkC oncogenicity relies on IGF1R activation269,270 and can cause 
hyperactivation of mTORC1271,272. Therefore, the mechanism of resistance to 
dasatinib, sunitinib and temsirolimus likely entailed TEL-TrkC dependent 
activation of the IGF1R signaling pathway, which stimulated mTORC1 
hyperactivation. This postulate was reinforced by the detection of drug 
synergistic effects of BMS-754807 and the ATP-competitive mTOR inhibitor 
dactolisib in 784_2 cells (Figure 27). On the other hand, no such effects were 
observed between BMS-754807 and trametinib, a MEK inhibitor, indicating 
that an additional signal leading to MEK addiction was involved in the disease 
pathogenesis of this patient.  
 
 
 
Figure 26. The drug resistance observed in patient 784 is defined by changes in 
clonal architecture and phosphoproteomics. Clones 1, 2 and 3 were present at 
diagnosis, clone 3 and low frequency of clones 4 and 5 before relapse (784_1) and 
clone 3 and expanded clones 4 and 5 after relapse (784_2). 
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Figure 27. Oncogenic driver signals in the AML evolution of patient 784. 
Combinatorial treatment of BMS-754807 and either dactolisib or trametinib in drug 
resistant patient cells identified synergy between mTOR and IGF1R/TrkC inhibition. 
Integration of molecular and functional data enabled generation of a model of drug 
sensitivity and resistance. Red means sensitivity and blue means resistance. 
 
14.3 Integration of functional and molecular data identifies mechanism 
of drug action 
 
The direct targeting of BCR-ABL1(T315I) by axitinib was further validated 
biochemically. In line with the engineered Ba/F3 cell assays, axitinib 
selectively inhibited the ABL1(T315I) kinase activity with similar potency as 
VEGFR2262,273, whereas its effects towards ABL1 were approximately 30-fold 
lower (Table 10).  
 
         Table 10. Kinase activity inhibition by axitinib measured with microfluidic  
         mobility shift assay 
Kinase Axitinib Ki (nM) 
VEGFR2 0.02 ± 0.004 
ABL1(T315I) 0.1 ± 0.03 
ABL1 3.8 ± 0.03 
  
To determine the biding interactions and axitinib’s preferential activity towards 
the mutated form of ABL1, X-ray crystallography was performed. The results 
showed that axitinib binds to ABL1 by forming 4 hydrogen bonds, 2 between 
the ABL1 kinase hinge segment and the indazole ring of axitinib and 2 
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between residues K271 and Y253 and axitinib’s amide (Figure 28). In 
addition, the co-crystal structures of axitinib:ABL1 and axitinib:ABL1(T315I) 
surprisingly demonstrated a contrasting difference in the conformations of the 
activation loop (A-loop) of the kinases. Axitinib bound ABL1 when the kinase 
was in an inactive or DGF-out conformation, while ABL1(T315I) in an active or 
DFG-in conformation. Interestingly, axitinib binds its primary target VEGFR2 
when the kinase adopts a DFG-out conformation (Figure 28). Furthermore, 
there was a difference in the P-loop conformation as well as large rotation of 
the axitinib:sulfur-indazole bond, which positioned the phenyl amide group in 
diverse binding pockets. Hence, in drug target interactions both the lock and 
the key can change.  
 
 
Figure 28. Co-crystal structures of axitinib bound to ABL1, ABL1(T315I) and 
VEGFR2 demonstrate different conformations of the inhibitor as well as the kinase.  
 
Previous studies have shown that the T315I mutation stabilizes the DFG-in 
kinase conformation274,275 and therefore the detected discrepancy in A-loop 
conformations of ABL1 and ABL1(T315I) most likely suggests an altered 
protein dynamics. Moreover, the increased potency towards the ABL1(T315I) 
kinase indicates that axitinib more optimally binds the DFG-in conformation of 
ABL1. This observation is supported with biochemical data that showed that 
axitinib more effectively inhibited autophosphorylated than non-
phosphorylated ABL1(T315I) with Ki = 149 pM and 421 pM, respectively. 
Another surprising finding from the structural studies was that axitinib 
occupied a distinctive binding space in comparison to all other clinically 
available ABL1 inhibitors. Axitinib was not in as close proximity to the T315I 
residue and alpha-C helix in comparison to dasatinib and ponatinib. The 
reason that axitinib remains active towards the gatekeeper residue is that it 
does not form a hydrogen bond with the T315 in the first place and hence 
does not clash unfavorably with the I315 substitution unlike other ABL1 
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inhibitors177. These findings of gatekeeper-selective inhibition could be utilized 
for the development of a novel class of ABL1 targeted drugs.  
 
A 35 year-old male was diagnosed with CML in lymphatic blast crisis and 
started on 600 mg imatinib monotherapy that led to a hematologic response 
(Figure 29). Two months later, the patient (FHRB.1408) had a hematologic 
relapse warranting a therapy switch to dasatinib (140 mg once-daily) to which 
no response was detected. At that point the kinase domain of BCR-ABL1 was 
sequenced, which revealed the presence of a T315I mutation in virtually all 
blast cells. The patient was subsequently treated with two cycles of CVAD 
(cyclophosphamide, vincristine, doxorubicin (also known as adriamycin), and 
dexamethasone) chemotherapy that reduced the relative T315I transcript 
levels to 20 percent. Mononuclear cells from this patient were then subjected 
to DSRT that detected leukemia selective sensitivity to immunomodulators, 
ATP-competitive mTOR inhibitors, ponatinib, axitinib, and MEK inhibitors 
(Figure 29). No response was seen to other ABL1 specific inhibitors.  
 
 
Figure 29. Clinical follow-up of patient 1408 and ex vivo and in vivo response to 
axitinib measured with DSRT, immunoblotting, and real-time quantitative PCR. BM-
bone marrow; BP-blast phase; CR-complete response; GrIV GVHD-grade IV graft 
versus host disease; KD-kinase domain; Ly-lymphatic; MR-molecular response (PCR 
test for quantification of BCR-ABL1 in bone marrow cells); PR-partial response; seq-
sequencing; wt-wild-type.  
 
Since majority of the candidate drugs were not clinically available when the 
screen was performed, including ponatinib, the patient was treated in an off-
label setting with the standard approved dose (5 mg twice daily) of axitinib for 
two weeks. Simultaneously, an immunoblotting analysis of CRKL (a surrogate 
marker of BCR-ABL1 activity) phosphorylation status in response to 
increasing concentrations of axitinib treatment of mononuclear cells from the 
same patient, prior to axitinib treatment, was performed. The results showed a 
dose-dependent reduction of CRKL phosphorylation in response to axitinib 
exposure, demonstrating that axitinib could inhibit BCR-ABL1 mediated 
signaling. The in vivo treatment of patient 1408 with axitinib led to the rapid 
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elimination of BCR-ABL1(T315I)-positive cells from the bone marrow as well 
as a 5-fold reduction of T315I transcript levels (Figure 29), implying that 
axitinib is capable of achieving on target efficacious responses in patients with 
BCR-ABL1(T315I) leukemias.  
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DISCUSSION and CONCLUSION 
 
With the emerging challenges of translating cancer genome information into 
clinically actionable strategies and predicting and circumventing resistance to 
targeted drugs, it is clear that more effective ways are needed of testing 
cancers functionally. Comprehensive molecular and functional profiling efforts 
on large numbers of cancer cell lines were recently published238,239,276-278 and 
the data from these studies showed to be valuable in linking molecular 
features of cancers to drug and compound sensitivities. However, the most 
powerful way of making these links would be to functionally and molecularly 
profile primary cancer samples and to follow one patient through different 
stages of disease to capture the plasticity of a cancer and emergence of 
resistance.  
 
This thesis presented an ‘Individualized Systems Medicine’ strategy involving 
comprehensive ex vivo drug sensitivity testing of patient cancer cells 
combined with molecular and genomic profiling. This approach allowed us to 
functionally identify selective sensitivities of primary leukemia cells to a broad 
array of targeted anti-cancer agents, which could facilitate the identification of 
subgroups of patients that are likely to respond to a specific therapy and 
possibly even serve as a direct diagnostic tool. In addition, study I and II 
showed that the ex vivo drug sensitivities can be translated into efficacious 
therapeutic strategies and importantly, that one can follow emergence of 
resistance in vivo in the ex vivo assay and rapidly identify remaining or novel 
emerging drug sensitivities in the resistant patient cases. Associations 
between molecular and functional patterns further enable disease follow-up, 
determining clonal architecture and optimization of individualized therapy. 
 
The overall goal of the thesis was to develop and implement a platform for 
functional and molecular characterization of cancer patient cells in order to 
gain a deeper understanding of disease pathogenetics as well as identify 
novel treatment strategies for individual patients. As disease models this 
thesis utilized primarily patient material from AML and Ph+ patients for both 
therapeutic and practical reasons. AML is intriguing to study, as even though 
it is a well-characterized disease9,76,80,279,280, the current genomic and 
molecular knowledgebase has not facilitated identification of efficacious 
therapies and improvement of patient outcome. In contrast, since the early 
2000’s CML has become the poster child for the targeted drug revolution with 
the discovery and development of ABL1-specific inhibitors that significantly 
improved the outcome of patients from 5-year survival below 50% to 90%281. 
However, development of resistance to therapy, frequently due to the 
occurrence of point mutations in the kinase domain of ABL1, such as the 
gatekeeper T315I mutation, poses a significant clinical challenge. Practical 
benefits to investigating hematological malignancies include easy sampling 
and acquisition of large number of cells, possibility to generate sequential 
samples from the same patient and lower genetic complexity than most solid 
tumors282.  
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The aim of the first study was to establish a drug testing approach to 
determine the sensitivity of hundreds of anti-cancer agents in primary AML 
cells with the aim of identifying novel treatment strategies and advancing the 
biological understanding of the disease. In the study, DSRT was applied to 28 
AML patient samples and 7 healthy bone marrow control samples to identify 
selective subgroups to a range of molecularly targeted compounds. Drug 
sensitivity was quantified with a newly established drug sensitivity score that 
integrates the entire dose response data, as individual activity metrics do not 
sufficiently capture the complete dose response information245. SA I described 
the method in detail and showed additional applications of the drug sensitivity 
scoring approach, thus illustrating that DSS could provide complementary	  
cognizance to genetic and epigenetic data on cancer phenotypes and 
addictions on a patient-by-patient basis. 
 
Overall, molecularly targeted signal transduction-type inhibitors exhibited a 
less toxic response in control samples and a greater signal window towards 
sensitive samples than conventional chemotherapeutics. Compounds from 
the latter group seldom exhibited selective responses in sample subgroups, 
for example cytarabine and topoisomerase II inhibitors, but those are often 
more challenging to interpret and translate from ex vivo to in vivo setting. The 
response to mitotic inhibitors, for example, was strongly correlated with the 
mitotic activity of a sample in the assay plate, which likely has little predictive 
power of the response in an in vivo situation. With that notion, mitotic 
inhibitors were excluded from clustering data sets to avoid that the ex vivo 
mitotic activity would drive the grouping of the patient samples.  
 
Among the signal transduction inhibitors that exhibited selective responses in 
subgroups of patient samples over control bone marrow samples were both 
major investigational oncology drug classes such as MEK inhibitors (although 
trametinib has since been approved for BRAF mutated melanoma), several 
tyrosine kinase inhibitors and ATP-competitive PI3K/AKT/mTOR pathway 
inhibitors, as well as approved rapamycin analog TORC1 inhibitors, JAK 
inhibitors and broad spectrum tyrosine kinase inhibitors such as dasatinib, 
sunitinib and sorafenib. Hence, the results point to the probability that already 
approved anti-cancer drugs, such as dasatinib (CML and Ph+ ALL), sunitinib 
(renal cell carcinoma and gastrointestinal tumors), and temsirolimus (renal cell 
cancer), could be explored for subsets of AML patients. Even though patients 
treated with DSRT-guided therapy did not achieve sustained cures, the 
clinical responses detected are promising in light of the fact that the patient 
cohort investigated was largely composed of relapsed and refractory patients 
with end stage disease. However, a fraction of patients that received DSRT-
tailored treatment achieved remission levels that allowed the patients to 
undergo HSCT, which still remains as the only curative treatment for AML 
patients. The translation of ISM results to the clinic is an effective way to 
generate hypothesis to be evaluated in formal clinical trials for investigational 
as well as already approved drugs. Moreover, the ISM strategy could be 
utilized for identification of efficacious drug combinations according to 
correlating drug sensitivities.  
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Five functional taxonomic subgroups were defined based on unsupervised 
clustering of the ex vivo drug sensitivity profiles of the AML patient samples. 
Each subgroup was characterized with either sensitivity or non-sensitivity to 
anti-apoptotic agents, immunosuppressants, MEK, JAK, PI3K/AKT/mTOR and 
broad TK inhibitors. This analysis illustrates how unbiased functional profiling 
of cancer cells can facilitate matching drugs to individual patients. 
Furthermore, the drug responses were compared to the most frequent 
somatic mutational events in AML (as identified in the TCGA AML study76). 
While the sample cohort in this study was significantly smaller than the one 
used in the TCGA study, still certain phenotype to genotype links could be 
identified. For instance, sensitivity to FLT3 inhibitors was a strong predictor of 
activating FLT3 mutations in subgroup V. However, it appears that it is not 
that simple and that patient samples falling in this group were also dependent 
on other TK signals targeted by inhibitors not inhibiting FLT3 such as 
dasatinib. This finding implies that there are cooperative signaling networks 
between oncogenic FLT3 signaling and one of TK whose combined targeting 
may provide an additional benefit in this patient population than FLT3 
inhibitors alone. A proof of principle of this approach was shown with the 
patient case 600, where combinatorial treatment of dasatinib and sunitinib 
(targeting FLT3) led to a profound clinical response and subsequent complete 
remission following 3 failed induction chemotherapies. This example further 
demonstrates the power of the ISM and DSRT approaches to identify 
treatment strategies even for heavily refractory patients with no alternative 
treatment possibilities in the clinic.  
 
MEK signaling has previously been suggested to play a role in AML 
pathogenesis283-288. Several MEK inhibitors have been in clinical trials for an 
AML indication, but none have been successful to date, possibly because no 
relevant patient stratification strategy was applied. Numerous trials have 
attempted to use the obvious predictive biomarker, the presence of NRAS 
mutations, and failed to yield positive results. In study I, 10 patient samples 
showed a highly selective sensitivity, indicating that the DSRT platform could 
be a way to identify candidate patients for MEK inhibitor therapy. While MEK 
addiction did not strongly link to sensitivity to a RTK inhibitor, a significant 
association was detected between activating RAS mutations or MLL fusions 
and MEK inhibitor sensitivity. However, approximately half of the sensitive 
patient samples did not harbor activating RAS mutations, suggesting that 
alternative or multiple upstream events may be involved in MEK addiction in 
AML such as baseline levels of ERK phosphorylation, constitutive activation of 
pathway components upstream of ERK, and expression of phosphatases 
(DUSP-4 and DUSP-6) and/or adaptor proteins (SPRY-2, SPRY-4, KSR1) 
that positively or negatively influence MAPK signaling260,286,289. Interestingly, 
recently AHR (encoding for aryl hydrocarbon receptor) expression was linked 
to MEK inhibitor sensitivity in NRAS mutant cell lines238 and a transcriptional 
pathway signature was identified for selumetinib sensitivity in melanoma, 
colon, breast and lung tumor cell lines290. Further studies are needed to 
elucidate the complete mechanism of MEK addiction in primary AML cells, as 
RAS mutations alone do not fully explain the sensitivity to MEK inhibitors, and 
improved understanding of how to utilize MEK inhibitors presumably in 
combinations with other drugs for effective AML therapy.  
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Several inhibitors in the PI3K/AKT/mTOR pathway were identified as patient 
sample-selective compounds. Upregulation of the PI3K/AKT/mTOR pathway 
has been reported in AML patient samples and it is associated with poor 
prognosis291,292. Surprisingly, a strong correlation between selective sensitivity 
to the approved rapalog TORC1 inhibitors and ATP-competitive inhibitors of 
either the upstream PI3K or AKT classes of enzymes or by ATP-competitive 
mTOR inhibitors was not observed. Along those lines, very low background 
toxicity was detected with rapalogs while the ATP-competitive 
PI3K/AKT/mTOR inhibitors generally had significant toxicities and narrower 
therapeutic windows. This finding further shows the predictive value of the 
DRST in that it matches the clinical situation with these classes of 
compounds. Rapalogs are generally exhibiting low levels of toxicity in vivo 
compared to the other PI3K/AKT/mTOR inhibitors, which historically have had 
issues with toxicity in the clinic. The effects of mTOR inhibitors have been 
studied in an AML context before with conflicting findings. One group reported 
rapalog sensitivity with a resulting inhibition of also TORC2 and AKT293, while 
another has reported that rapalog-induced TORC1 inhibition leads to 
activation of PI3K/AKT via upregulation of IGF1R signaling272. In our setting, 
the investigational IGF1R inhibitor BMS−754807 interestingly exhibited a 
response pattern very similar to ATP-competitive mTOR and PI3K inhibitors. 
Activated AKT has been detected and associated with poor prognosis in over 
50% of AML patient samples294 and activation of the AKT pathway was 
suggested to link to drug resistance in AML in others138,295. However the 
response to the AKT inhibitor MK-2206 was quite divergent than that of either 
rapalogs or PI3K or mTOR inhibitors. A study by Recher and colleagues 
reported in vitro anti-cancer activity of sirolimus in 4 out of 9 samples from 
patients with either refractory/relapsed or de novo AML296, but rapalogs as 
monotherapy or in combination with high dose chemotherapy in relapsed and 
refractory AML patients have not proven clinically successful to date297,298. 
Hence, ongoing efforts are made to identify synergistic partners of rapalogs 
for efficacious AML therapy, for example as reported here rapalogs in 
combination with dasatinib or other potent broad tyrosine kinase inhibitors 
such as tivozanib, axitinib (that both appear to have related targets as 
dasatinib in AML), sunitinib or sorafenib. 
 
In addition, study I showed that dasatinib, a broad tyrosine kinase inhibitor 
approved for use in BCR-ABL1-driven leukemias, stood out as one of the 
most selective RTK inhibitors in a subset of AML patient samples. ABL1 is not 
yet recognized as a significant driver kinase in AML and subsequently, 
dasatinib has not been studied extensively in the context of this disease. 
However, reports reveal a role for dasatinib in promoting ATRA-induced 
differentiation of AML cells299 as well as prolonged in vivo differentiation of 
AML blasts carrying the t(8;21) translocation to mature, moderately functional 
neutrophils300. In addition, others have shown that dasatinib hinders growth of 
molecularly heterogeneous AML cell lines and that it caused 
dephosphorylation of hyperactivated Lyn kinase in AML patient samples301. 
Drug sensitivity profiles showed that dasatinib was selective and effective 
primarily in AML M5 diagnosed patient samples ex vivo and in combination 
with temsirolimus and sunitinib in vivo in an AML M5 patient with a FLT3-ITD 
mutation. In accordance, in a separate study, dasatinib sensitivity was only 
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seen in a patient diagnosed as AML M5b among a diverse panel of 8 AML 
patient samples302. The overall DSRT data does not indicate that the effect of 
dasatinib is due to single inhibition of Lyn or any other SRC family kinase, 
since other tested inhibitors targeting the same family of kinases (e.g. 
saracatinib) had different sensitivity profiles at the same time as several 
inhibitors that do not target SRC family kinases (e.g. tivozanib and axitinib) 
exhibited response patterns across the patient samples that were correlative 
to, but not as potent as the one of dasatinib. No obvious kinase target linked 
dasatinib to these inhibitors, so it is likely that these AML M5-selective kinase 
inhibitor sensitivities either depend on the inhibition of a combination of 
kinases or on non-kinase targets of these inhibitors. Nonetheless, dasatinib 
either as a single agent or in combination with chemotherapy or other targeted 
agents (e.g. temsirolimus or quizartinib) is a promising novel therapeutic 
strategy for relapsed and refractory AML M5 patients. 
 
Overall the DSRT approach not only systematically validated candidate drugs 
that would otherwise be merely hypothesized based on genomic information, 
but also uncovered cancer cell addictions and dependencies that could not 
directly be deduced from molecular profiling data. The quantification of 
selective drug responses in our DSRT approach allowed for identification of 
drugs that exhibit leukemia-selective effects and hence likely have less 
toxicity. Comprehensive integrated analysis of phenotypes and genotypes in 
serial samples from individual patients facilitated optimization of personalized 
therapy, disease monitoring and follow up of the clonal composition of the 
cancer. Application of this approach to two case studies highlighted the 
significance of continual functional profiling of cancer cells in order to identify 
variations in drug sensitivities. On the one hand in patient 600 following 
relapse to dasatinib, sunitinib and temsirolimus treatment an omni-resistance 
phenotype was observed ex vivo that could not be completely explained by 
alterations in molecular profiles. On the other in patient 784 the response to 
that combinatorial therapy was lost likely due to enrichment of a clone 
harboring an ETV6-NTRK3 fusion gene encoding for an oncogenic tyrosine 
kinase that is a known driver in AML and other cancer types303-305 and 
possibly could have been targeted by combinatorial inhibition of IGF1R and 
mTOR. 
 
Besides to AML, the ISM/DSRT strategy was applied to Ph+ leukemias in 
study II, which led to the unexpected discovery that the VEGFR2 inhibitor 
axitinib also exhibits potent and selective BCR-ABL1(T315I) inhibitory activity. 
Currently, the only clinically available ABL1-specific inhibitor that has efficacy 
in this patient population is ponatinib198,200, but vascular adverse events202,306 
and selection of resistant compound mutations199,211 limit its clinical utility. 
Since the T315I mutation occurs in 15-20% of refractory CML and Ph+ ALL 
patients, there is a clear need for novel therapies with favorable safety profile. 
Integration of the functional ex vivo DSRT data with biochemical and 
structural analysis led to further validation that axitinib specifically targets 
BCR-ABL1(T315I) through a mutation-induced kinase conformational change 
distinct from its ABL1 and VEGFR2 binding modes. Given that axitinib 
occupies a very different binding space than other ABL1 inhibitors and has a 
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narrow target specificity profile, suggests that it will have a unique mutation 
vulnerability and favorable safety profile. 
 
There have been previous reports of compounds exhibiting efficacy against 
the gatekeeper mutation in addition to ponatinib197,261,307, but this effect was 
likely due to promiscuous nature246 of the agents as their clinical use has 
been hindered by toxicity. Study II clearly illustrates that axitinib could be a 
beneficial addition to the ABL1 targeting toolbox due to its largely unique 
selectivity and binding to the gatekeeper mutation and limited 
polypharmacology. The distinct drug-target interaction features revealed by 
the axitinib-ABL1(T315I) binding could serve as an exemplar for development 
of even more effective gatekeeper-mutant selective inhibitors targeting ABL1 
as well as other clinically important kinases, such as EGFR and KIT. Hence 
the findings of the study reflect a significant new concept where a kinase 
inhibitor selectively targets a subset of resistance mutations, which might 
have important implications in precision cancer medicine in the future. It is 
notable that clinical resistance mutations are occurring with virtually all TKIs to 
date and utilizing narrow targeted mutation selective inhibitors might be a 
simpler and less toxic approach to targeting new resistance mutations than 
developing individual inhibitors with an even broader spectrum. 
 
Axitinib received regulatory approval in the USA and Europe in 2012 for the 
treatment of advanced renal cell carcinoma following failure to prior therapy. 
Clinical experience with the drug points to favorable safety profile with 
manageable side effects308-310. Therefore, study II stipulates that axitinib 
should be formally explored in patients with BCR-ABL1(T315I)-driven 
leukemia in a fast-track mode. Given the ABL1(T315I)-selective activity of 
axitinib, it is conceivable that T315I-negative clones might take over in 
response to axitinib treatment in vivo, especially since in patients not all blast 
cells might be T315I positive. Hence, combinations of axitinib with either other 
ABL1 inhibitors or inhibitors of downstream BCR-ABL1 effector signals (e.g. 
MEK, PI3K/mTOR, SMO) should provide a more complete clonal coverage 
and consequently more effective leukemia treatment. Since axitinib does not 
exhibit analogous adverse effects or overlapping toxicities311,312 with other 
approved ABL1 drugs, it might be an ideal candidate for combinatorial 
approaches. However, the majority of ABL1 drugs on the market inactivate 
their metabolizing enzyme CYP3A4, which also metabolizes axitinib. It could 
therefore be challenging to determine dosing that avoids severe adverse 
effects of axitinib. Bosutinib, on the other hand, does not inhibit CYP3A4 and 
may therefore be a good combination partner with axitinib and might facilitate 
broad mutation coverage treatment. Previous research has shown that 
intermittent exposure of ABL1 inhibitors is sufficient for committing BCR-ABL1 
positive cells to apoptosis and reduction of adverse effects such as pleural 
effusions313,314. Thus it is possible that the adverse effects of axitinib (on-
target VEGFR-driven) could be reduced by non-continuous inhibition since 
both on- and off-target effects of inhibiting VEGFRs typically come from 
persistent inhibition315. 
 
While the ISM strategy is a powerful method for customizing patient treatment 
and identification of biomarkers that explain drug responses, the number and 
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types of drugs currently available limit the approach. The oncology drug 
collection used in these studies is heavily biased towards kinase inhibitors, 
which have an inherent problem of short effective response duration and rapid 
onset of resistance that is often very challenging if not impossible to 
overcome. However, the DSRT platform is adaptable to different types of 
drugs and drug classes that can be fed in as they become available providing 
the opportunity to interrogate a vast array of targets. Despite the use of 
primary patient material in this thesis, it is likely that some of the tumor 
complexity in terms of cell differentiation and tumor microenvironment is lost 
on plastic. Hence, improved culture conditions that preserve the state of the 
cancer cells and take into account the tumor environment might enhance the 
predictive power of ex vivo drug sensitivity testing approaches as well as 
provide additional insights into disease biology. Furthermore, to validate that 
this approach accurately predicts drug responses and can be of significant 
benefit to patients it will need to be evaluated in a formal clinical trial. This 
would be contingent on several pharmaceutical companies providing their 
drugs for a bucket trial design, which is not an easy or simple feat. As most 
cancer patients are treated with drug combinations, the DSRT pipeline will 
also need to be adapted to systematic drug combination testing as well as 
means to assess or predict toxicity of individual as well as combined drugs. 
While single agents are easier to implement and verify, often no long-term 
responses are achieved. In contrast, combinatorial therapy might produce 
longer-lasting responses, but the challenge remains on how best to design it 
whether based on correlative drug responses from profiling data, addition of 
chemotherapy to an experimental drug or based on distinct mode of action. 
 
In conclusion, pharmacopeia-wide drug sensitivity and resistance testing led 
to the identification of several classes of signal transduction inhibitors that 
exhibited selective activity in distinct and partly overlapping subsets of AML 
patient samples. Network analysis of associated inhibitors and their target 
selectivities allowed us to reveal clues to cancer molecular pathogenesis and 
driver addictions in the patient samples. It is likely that the DSRT data 
integrated with molecular profiling and clinical information will become a 
powerful tool to link selective drug responses to clinically actionable markers, 
patient stratification and novel therapeutic strategies for managing and curing 
aggressive cancers. This integrated systems biology approach is an effective 
hypothesis generator to be explored in future clinical trials. The data 
presented in this thesis further shows the power of unbiased functional 
profiling of patient derived cancer cells in identifying novel drug-target and 
drug-patient interactions with broad implications. Moreover, a novel functional 
classification of AML was introduced that can be further refined with a larger 
cohort of patients and be of benefit for improved patient stratification and 
drug-patient matching. The studies included in this thesis emphasize the 
benefit of drug repurposing and investigating new uses of already existing 
drugs as well as illustrate that DSRT can serve as a drug positioning and de-
risking tool of investigational compounds. A future goal will be the systematic 
testing of the diagnostic value of the DSRT approach in identifying sensitive 
patient subgroups and possible adverse effects in a clinical setting as well to 
evaluate whether DSRT-based therapy as first line rather then chemotherapy 
might prevent relapse and progressive disease evolution. In addition, adapting 
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the platform to testing drug combinations ex vivo, developing more 
comprehensive readouts as well as detecting the impact of drug treatment on 
cell signaling and clonal composition might improve the predictive power of 
the DSRT. 
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